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ABSTRACT 
 
The aim of my Ph.D. research is to develop a new, transformative cancer targeted therapy 
via the combination of unnatural sugar-mediated controlled metabolic cell labeling and 
bioorthogonal Click chemistry. By controlling the metabolic glycoengineering processes of 
unnatural sugars via rational chemistry designs, I was able to design a library of trigger-
activatable sugar precursors that can label cell surface with chemical groups (e.g., azides) only in 
the presence of either exogenous triggers (ultraviolet (UV)) or endogenous triggers (H2O2, tumor 
hypoxia, NAD(P)H dehydrogenase quinone 1 (NQO1), and histone deacetylase 
(HDAC)/cathepsin L (CTSL)). Among them, HDAC/CTSL-responsive acetylated azidomannose 
(DCL-AAM) mediated excellent cancer-specific labeling in vitro and in vivo, which enhanced 
tumor accumulation of dibenzocyclooctyne (DBCO)-drug conjugates via efficient Click 
Chemistry between azides and DBCO and consequently exerted robust anticancer activities 
against LS174T colon cancer, MDA-MB-231 triple-negative breast cancer, and 4T1 metastatic 
breast cancer in murine models. DCL-AAM coupled with DBCO-drug conjugates, a new cancer 
targeted therapy which I name as Active Tissue Targeting via Anchored ClicK Chemistry 
(ATTACK), is essentially the small molecule version of antibody/antigen targeting technology 
and shows multiple advantages. Apart from the efforts in rational chemical designs of azido-
sugars, I also developed sugar-loaded micelles and microbubbles for tumor labeling and 
targeting, in an effort to fully evaluate the advantages of Click chemistry-based cancer targeting 
strategy. Last but not least, I demonstrated that different types of unnatural sugars (e.g., azido-
mannose and azido-galactose) have distinct labeling efficiencies in varying cancer types and that 
the use of reversible chemistries can impart the recyclability of cell-surface chemical receptors. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
1.1.1 Cell-surface receptors for cancer targeting 
Cell-surface receptors play a vital role in regulating the interactions between cells and the 
extracellular microenvironment.
1-3
 Manipulating the expression and functionality of cell-surface 
receptors can be critical in controlling the influx of extracellular materials of interest, such as 
therapeutic agents, to target cells. There has been consensus that the recognition of disease-
specific, cell-surface receptors enables the targeted delivery of therapeutic agents to diseased 
cells and minimizes undesired side effects. Based upon lineage-specific genome sequences, 
different cell types possess varying populations of cell-surface receptors.
4-6
 In addition, diseased 
cells harboring genetic mutations have the capacity to express altered receptor populations.
7-9
 For 
instance, as a consequence of gene amplification, some breast cancer cells overexpress human 
epidermal growth factor receptor 2 (HER2/neu), which permitted the development of various 
cancer-targeting drugs.
10-12
 However, the differences in endogenous receptor populations 
between diseased and normal cells cannot always be exploited as therapeutic targets as they 
might be either too small to impart high selectivity or specific receptors are simply not expressed 
by target cells of interest.
13-15
 For example, overexpression of HER2 is only limited to 15 to 20 
percent of breast cancers, hence the majority of women with breast cancers would not benefit 
from HER2-specific targeted therapies.
16, 17
 Given the limitations of exploiting endogenous 
receptors as druggable targets, alternative strategies to manually manipulate cell-surface 
receptors to differentiate cell types are being actively pursued.  
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Two main strategies have been exploited to manually manipulate cell-surface receptors. The 
first strategy is to directly amplify the expression of existing cell-surface protein receptors using 
gene transfection method as described where the overexpression of HER2 in mouse NIH 3T3 
cells was achieved by using a HER2-encoding plasmid.
18
 However, this strategy is of limited 
translational applicability given the stringent technical requirements, non-selectivity over cell 
types in vitro and in vivo, and potential detrimental effects to the treated cells.
18, 19
 Instead of 
directly increasing the amount of cell-surface protein receptors, a different strategy has been 
attempted, which is to introduce unique chemical functional groups onto the cell surface as an 
alternative to protein receptors.
20
 These manually introduced chemical functional groups can 
mimic the receptor function of cell-surface proteins and facilitate the cellular uptake of target 
extracellular materials via efficient chemistries.
21
 
 
1.1.2 Unnatural sugar-mediated metabolic cell labeling 
Previous attempts have been made to site-specifically incorporate unnatural amino acids into 
transmembrane proteins by using mutant aminoacyl-tRNA synthetases and suppressor tRNAs.
22-
24
 However, the necessity of gene insertion and introduction of tRNA synthetase makes this 
methodology rather complicated to use, in particular in vivo.
25
 An alternative method to 
introduce chemical functional groups onto the cell surface is the use of metabolic 
glycoengineering of unnatural sugars, as initiated by Bertozzi et al..
20, 26, 27
 Unnatural sugars 
bearing chemical functional groups could participate in the metabolic glycoengineering 
processes in cells and be expressed on the cell surface in the form of glycoproteins. This 
methodology is very simple in technique, by directly incubating with target cells, and can easily 
display numerous functional groups on cell-surface proteins with desired density. For these 
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reasons, unnatural sugar-mediated metabolic cell labeling has been widely used for cell 
modification and cell targeting. However, to achieve more extended applications, a lot of efforts 
are still needed to understand and further manipulate the labeling processes. For example, 
because unnatural sugar-mediated cell labeling also happens in normal cells, any method to 
modify the sugars to enable cancer-selective labeling will greatly facilitate the application of 
sugar labeling to cancer targeting.
28,29
 Also, the labeling efficiency and pharmacokinetic 
properties of different types of unnatural sugars remain unknown. Overall, metabolic sugar 
labeling provides a powerful tool for manual manipulation of cell-surface receptors, but 
numerous challenges remain to be addressed to fully realize its potential applications in cancer 
targeting, cell signaling and imaging, etc.  
 
A variety of chemical functional groups such as azides, alkynes, ketones and aldehydes can 
be incorporated into cell-surface glycoproteins via unnatural sugar mediated metabolic 
labeling.
20, 21, 30
 These introduced chemical groups can mediate targeted delivery of extracellular 
therapeutic drugs via efficient chemistries such as Click chemistry between azide and 
alkyne/cyclooctyne, Staudinger ligation, and reaction between ketone/aldehyde and hydrazine.
31-
33
 These chemistries are bioorthogonal without interference with native biochemical processes, 
and can happen under physiological conditions. Among the bioorthogonal chemistries developed, 
copper-free Click chemistry between azide and DBCO is the most widely-used and efficient for 
bioconjugation, cell labeling, and cancer targeting, especially in vivo.
31, 34-36
 
 
1.1.3 Metabolic sugar labeling coupled with Click chemistry for cancer targeting 
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Metabolic sugar labeling, coupled with bioorthogonal Click chemistry, has shown great 
potential for cancer targeting via a two-step strategy.
37-40
 In the first step, unnatural sugars 
bearing chemical functional groups (e.g., azides) are delivered to and metabolized in cancers, 
followed by the cancer targeting of DBCO-bearing therapeutic agents via copper-free Click 
chemistry in the second step. For example, Kim group
37
 reported that azido-sugars that were 
intratumorally injected into the implanted tumors in mice successfully labeled tumor cells with 
azido groups and improved the tumor accumulation of subsequently intravenously injected 
DBCO-Cy5 via Click chemistry. They also reported the use of chitosan nanoparticles to deliver 
azido-sugars to the tumor area for subsequent tumor targeting of DBCO-modified 
nanomedicine.
38
 
 
Compared to conventional protein-based targeting strategies, Click chemistry-based cancer 
targeting strategy possesses multiple obvious advantages. First, DBCO is a small “targeting” 
molecule and therefore can potentially avoid immune response and allow deeper penetration in 
solid tumors. Second, the reaction between azide and DBCO should be much more efficient and 
selective than protein interaction. Considering the potential much larger density of cell-surface 
sugars than proteins, the targeting can be much more efficient. Third, receptor saturation is no 
longer a problem as the amount of azido-sugars that could be expressed on the cell surface can 
be much greater than protein receptors. Lastly, DBCO as the targeting ligand can be easily 
incorporated into therapeutic agents or nanomedicines with a much higher density than 
conventional protein ligands without sacrifice of desired physiochemical and pharmacological 
properties. However, as mentioned above, cancer-selective labeling of cancers using unnatural 
sugars remains a great challenge.
28,29
 Nanoparticle-mediated delivery of azido-sugars can 
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improve the tumor accumulation and metabolic expression of azido groups in the tumor area, but 
the labeling selectivity between cancer cells and normal cells is far from satisfactory. 
 
1.2 Scope and Organizations 
My Ph.D. research focused on the development of cancer-selective labeling strategy via 
rational design of unnatural sugars and the evaluation of Click chemistry-based cancer targeting 
strategy. I also studied the sugar type-dependent metabolic labeling in varying cancers and 
evaluated the feasibility of applying reversible Click chemistry for continuous cancer targeting. 
The flow of my thesis is summarized in Figure 1.1. In Chapter 2, I will introduce the controlled 
labeling strategy of unnatural sugars and the excellent in vivo cancer targeting effect mediated by 
Click chemistry. Starting from these two main findings, multiple research projects are developed 
and will be separately described in Chapter 3-8. For example, based on the controlled labeling 
strategy developed in Chapter 2, I developed an enzyme-activatable sugar compound, DCL-
AAM, with superior cancer-labeling specificity both in vitro and in vivo, which will be 
introduced in Chapter 3. Chapter 4 will focus on the development of ATTACK cancer targeting 
technology (DCL-AAM coupled with DBCO-drug conjugates) and its application in inhibiting 
the growth of multiple cancer models. Chapter 5 and 6 will describe the use of nanoparticles and 
microbubbles for cancer targeted delivery of azido sugars, in an effort to demonstrate the 
advantages of Click chemistry-based cancer targeting strategy. All unnatural sugars mentioned in 
Chapter 2-6 are mannose derivatives. In fact, different types of unnatural monosaccharides have 
distinct in vivo biodistribution profiles and labeling efficiency in varying cancers, and I will 
compare galactose with mannose for liver cancer labeling and targeting in chapter 7. In Chapter 
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8, I will briefly mention the use of reversible Click chemistry instead of copper-free Click 
chemistry for cell labeling and targeting.   
 
 
 
Figure 1.1 Summary of the contents of my dissertation 
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CHAPTER 2 
CONTROLLED CELL LABELING OF UNNATURAL SUGARS 
 
2.1 Introduction 
Metabolic glycoengineering process of unnatural sugars provides a facile method to 
introduce chemical functional groups onto the surface of cancer cells with desired density.
1-4
 
These chemical groups, coupled with bioorthogonal Click chemistry, enable the development of 
a highly efficient cancer-targeting technology.
5-7
 However, unnatural sugars that have been 
reported can also label normal cells and thus the selective labeling of cell types of interest (e.g., 
target cancer cells) remains a substantial challenge.
8,9
 I reasoned that controlled labeling 
capability of unnatural sugars could be achieved via rational chemical design, that is, through 
chemical modification, we may be able to block the labeling process of existing unnatural sugars. 
If the chemical modification can be reverted within the cancer cells, the labeling capability of 
unnatural sugars might be reactivated in a trigger-dependent manner. 
 
I first focused on tetraacetyl-N-azidoacetylmannosamine (Ac4ManAz), a well-known cell 
labeling agent with the metabolic labeling process illustrated in Scheme 2.1. Ac4ManAz is 
hydrolyzed by non-specific esterase upon entering the cells (Step 1), followed by the 
phosphorylation of C6-OH (Step 2) and the isomerization from cyclic to open-chain structure 
(Step 3). The open-chain azidomannose then undergoes the aldol reaction with intracellular 
phosphoenolpyruvic acid (PEP) (Step 4) followed by the rearrangement and dephosphorylation 
reactions to form azido sialic acid (Step 5-6), which is conjugated to glycoprotein (Step 7-8) and 
expressed on the cell surface (Step 9).
8,10,11
 As Step 4-8 are downstream reactions largely 
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controlled by cellular processes, I reason that controlling the upstream reactions, in particular the 
site-specific Step-2 and Step-3 reactions, may allow manipulation of sugar metabolic activity. 
Compared to the phosphorylation reaction at the C6 position (Step 2), the formation of open-
chain aldehyde form of azidomannose at the C1 position (Step 3) is more critical for the 
downstream reactions (Step 4-9) as the Step-4 aldol reaction happens directly at the C1 position. 
I further reason that replacing the anomeric acetyl group (C1-OAc) of Ac4ManAz with a 
protecting ether bond (glycosidic bond) (the glycosidic protecting group is denoted as “P”, 
Scheme 1a) which can efficiently prohibit the deacetylation at the C1 position (Step 1’) and 
subsequent isomerization (Step 4’) may block the whole labeling process. Controlled labeling of 
cell types of interest may therefore be realized by designing target-specific, trigger-responsive 
ether bond caged Ac3ManAz derivatives (Step 1’-3’ followed by Step 3-9). Selective labeling of 
cancer cells would also be possible by using Ac3ManAz derivatives that are responsive to 
specific cancer-associated triggers such as redox dysregulation, elevated oxidant level, and 
overexpressed enzymes.
12, 13
 
 
2.2 Materials and Methods 
2.2.1 General  
Materials. D-Mannosamine hydrochloride and other materials were purchased from Sigma-
Aldrich (St. Louis, MO, USA) unless otherwise noted. N-hydroxysuccinimide (NHS) was 
purchased from Acros Organics (Renningen, Germany). DBCO-Cy5 was purchased from 
KeraFAST, Inc (Boston, MA, USA). EZ-Link
TM
 phosphine-PEG3-biotin, streptavidin-
horseradish peroxidase (HRP), and Pierce ECL western blotting substrate were purchased from 
Thermo Fisher Scientific (Waltham, MA, USA). DBCO-NHS was purchased from Conju-Probe 
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(San Diego, CA, USA). Anhydrous dichloromethane (DCM), hexane, ethyl acetate, diethyl ether, 
tetrahydrofuran (THF) and dimethylformamide (DMF) were purified by passing them through 
alumina columns and kept anhydrous by storing them in the presence of molecular sieves. 
Phosphate-buffered saline (PBS) and Dulbecco’s Modified Eagle Medium (DMEM) were 
obtained from Invitrogen (Carlsbad, CA, USA). Fetal Bovine Serum (FBS) was obtained from 
Lonza Walkersville Inc (Walkersville, MD, USA). BD Falcon culture plates were purchased 
from Fisher Scientific (Hampton, NH, USA). ProLong Gold antifade reagent was purchased 
from Life Technologies (Carlsbad, CA, USA). 
 
Instrumentation. Nuclear magnetic resonance (NMR) analyses were conducted on a Varian 
U500 (500 MHz) or a VXR500 (500 MHz) spectrometer. Infrared spectra were recorded on a 
PerkinElmer 100 serial FTIR spectrophotometer (PerkinElmer, Waltham, MA, USA). 
Electronspray ionization (ESI) mass spectra were obtained from Waters ZMD Quadrupole 
Instrument (Waters, Milford, MA, USA). HPLC analyses were performed either on a Beckman 
Gold system (Beckman Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a 
System Gold 128 UV detector and an analytical C18 column (Luna C18, 250*4.6 mm, 5 μm, 
Phenomenex, Torrance, CA, USA) or on a Shimadzu CBM-20A system (Shimadzu, Kyoto, 
Japan) equipped with a SPD20A PDA detector (190-800 nm), a RF10Axl fluorescence detector, 
and an analytical C18 column (Shimadzu, 3 µm, 50*4.6 mm, Kyoto, Japan). Lyophilization was 
conducted in a Labconco FreeZone lyophilizer (Kansas City, MO, USA). UV light (365 nm) was 
generated from an OmiCure S1000 UV lamp (EXFO, Mississauga, Canada). Confocal laser 
scanning microscopy (CLSM) images were taken on a Zeiss LSM 700 Confocal Microscope 
(Carl Zeiss, Thornwood, NY, USA). Flow cytometry analyses of cells were conducted with a BD 
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FACS Canto 6-color flow cytometry analyzer (BD, Franklin Lakes, NJ, USA). Fluorescence 
intensity of cells was measured on an IN Cell Analyzer 2200 system (GE Healthcare Life 
Sciences, Pittsburgh, PA, USA). In vivo and ex vivo images of animals were taken either on the 
Maestro In-Vivo Fluorescence Imaging System (CRI, Woburn, MA, USA) or on the Bruker In-
Vivo Imaging System (Bruker, Billerica, MA, USA). Bioluminescence images of animals were 
taken on the Bruker In-Vivo Imaging System (Bruker, Billerica, MA, USA). Protein bands were 
visualized by using X-ray imaging or Image Quant LAS 4010 (GE Healthcare, Little Chalfont, 
UK). Frozen tissues were embedded with optimum cutting temperature (O.C.T.) compound 
(Sakura Finetek USA, Torrance, CA, USA), sectioned by a Leica CM3050S Cryostat, and 
mounted onto glass slides.  
 
Cell culture. LS174T colon cancer was purchased from American Type Culture Collection 
(Manassas, VA, USA). 4T1 cells engineered with firefly luciferase were provided by Dr. David 
Piwnica-Worms from Washington University (St. Louis, MO, USA). Cells were cultured in 
DMEM containing 10% FBS, 100 units/mL Penicillin G and 100 μg/mL streptomycin 
(Invitrogen, Carlsbad, CA, USA) at 37
o
C in 5% CO2 humidified air. 
 
Animals. Female athymic nude mice were purchased from Charles River (Wilmington, MA, 
USA). Feed and water were available ad libitum. Artificial light was provided in a 12 h/12 h 
cycle. The animal protocol was reviewed and approved by the Illinois Institutional Animal Care 
and Use Committee (IACUC) of University of Illinois at Urbana-Champaign. 
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2.2.2 Synthesis of Ac3ManAzEt and Ac3ManAzNB. Ac4ManAz (0.1 mmol) and ethanol or 2-
nitrobenzylalcohol (0.3 mmol) were dissolved in dry dichloromethane. Boron trifluoride etherate 
(0.5 mmol) was added. The mixture was stirred overnight and then washed with saturated 
sodium bicarbonate solution and water. The organic phase was collected and concentrated to 
yield yellow oil. The crude product was purified by silica gel column chromatography using 
ethyl acetate/hexane (1/1, v/v) as the eluent. Ac3ManAzEt: 
1
H NMR (CDCl3, 500 MHz): δ (ppm) 
6.52 (d, 1H, C(O)NHCH), 5.35 (dd, 1H, CH2CHCHCH), 5.13 (t, 1H, CH2CHCHCH), 4.77 (d, 
1H, NHCHCHO), 4.58 (m, 1H, NHCHCHO), 4.11&4.23 (ddd, 2H, CH2CHCHCH), 4.05 (s, 2H, 
C(O)CH2N3), 3.99 (m, 1H, CH2CHCHCH), 3.54&3.73 (dq, 2H, CH3CH2O), 1.98-2.12 (s, 9H, 
CH3C(O)), 1.25 (t, 3H, CH3CH2O). 
13
C NMR (CDCl3, 500 MHz): δ (ppm) 170.8, 170.3, 170.0, 
166.9, 98.7, 69.5, 68.3, 66.1, 64.3, 62.4, 52.7, 51.1, 21.0, 20.9, 20.9, 15.1. ESI MS (m/z): 
calculated for C16H24N4O9Na [M+Na]
+
 439.2, found 439.2. Ac3ManAzNB: 
1
H NMR (CDCl3, 
500 MHz): δ (ppm) 8.12 (d, 1H, Ph, CHCHCHCHNO2), 7.79 (d, 1H, Ph, CHCHCHCHNO2), 
7.72 (t, 1H, Ph, CHCHCHCHNO2), 7.50 (t, 1H, Ph, CHCHCHCHNO2), 6.57 (d, 1H, 
C(O)NHCH), 5.41 (dd, 1H, CH2CHCHCH), 5.19 (d, 1H, C(O)NHCHCHO) 5.16 (t, 1H, 
CH2CHCHCH), 4.94 (t, 2H, OCH2Ph), 4.76 (m, 1H, C(O)NHCHCHO), 4.13&4.25 (ddd, 2H, 
CH2CHCHCH), 4.06 (s, 2H, C(O)CH2N3), 4.02 (m, 1H, CH2CHCHCH), 2.01-2.13 (s, 9H, 
CH3C(O)). 
13
C NMR (CDCl3, 500 MHz): δ (ppm) 170.8, 170.0, 167.0, 134.4, 128.8, 128.7, 
125.2, 98.7, 69.5, 69.0, 66.6, 65.8, 62.3, 52.7, 50.4, 21.0, 20.9, 20.8. ESI MS (m/z): calculated for 
C21H25N5O11Na [M+Na]
+
 546.2, found 546.2. 
 
2.2.3 UV induced degradation of Ac3ManAzNB. Ac3ManAzNB (1 mg) was dissolved in 
methanol/H2O (1.0 mL) and stirred at room temperature under UV irradiation. The intensity of 
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UV irradiation was set at 10 mW/cm
2
. At selected time points (0, 5, 15, and 30 min), HPLC and 
ESI MS measurements were conducted.  
 
2.2.4 Synthesis of phenyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol. A 
dry and nitrogen-flushed 25 mL Schlenk tube, equipped with a magnetic bar, was charged with 
4-iodophenylboronic acid pinacol ester (396 mg, 1.2 mmol). Anhydrous THF (2 mL) was added 
through a syringe and the solution was cooled to -78
o
C.  iPrMgCl
.
LiCl (0.92 mL, 1.3 M in THF) 
was added dropwise over 10 min. The reaction mixture was stirred at -78 
o
C for 3 h. 
Benzaldehyde (106 mg, 1.0 mmol) was added and the resulting mixture was stirred for another 
16 h at room temperature. The reaction was quenched with a small amount of saturated NH4Cl 
solution, extracted with Et2O for four times (4 × 10 mL) and dried over Na2SO4. After filtration, 
the solvent was evaporated under vacuum and the product was purified by flash silica column 
using hexane/ethyl acetate (3/1 to 1/1) as the eluent to yield light yellow oil (60% yield, 185 mg).  
 
2.2.5 Synthesis of Ac3ManAzBB. Phenyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)methanol (31.0 mg, 0.1 mmol) and Ac4ManAz (43.0 mg, 0.1 mmol) were dissolved in 
dry DCM (1.5 mL) and purged with nitrogen for 10 min. Boron trifluoride etherate (70.9 mg, 0.5 
mmol) was added through a syringe. The mixture was stirred overnight at room temperature in 
the dark. DCM (20 mL) was added and the solution was washed with saturated sodium 
bicarbonate solution twice (10 mL × 2) and DI water twice (10 mL × 2), respectively. The 
organic phase was collected, dried over anhydrous sodium sulfate and concentrated to yield 
yellow oil. The crude product was purified by silica gel column chromatography using ethyl 
acetate/hexane (1/1, v/v) as the eluent to yield yellow oil. 
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2.2.6 Degradation study of Ac3ManAzBB. Ac3ManAzBB (1.0 mg) was dissolved in methanol 
(1.0 mL). H2O2 aqueous solution (10 mM) was added and the reaction mixture was stirred at 
37
o
C. 20 μL of the reaction mixture was taken out and diluted to 600 μL for HPLC 
measurements at selected time points. 
 
2.2.7 General procedures for confocal imaging of azido-sugar labeled cells. Cells were seeded 
onto coverslips in a 6-well plate at a density of 4×10
4
 cells per well and allowed to attach for 12 
h. Azido-sugar (50 μM) was added and the cells were incubated at 37oC for 72 h. After washing 
with PBS, cells were incubated with DBCO-Cy5 (50 μM) for 1 h and fixed with 4% 
paraformaldehyde (PFA) solution, followed by staining of cell nuclei and membrane with DAPI 
(2 μg/mL) and CellMask orange plasma membrane stain (1 μg/mL), respectively. The coverslips 
were mounted onto microscope slides and imaged under a confocal laser scanning microscope. 
 
2.2.8 General procedures for flow cytometry analysis of azido-sugar labeled cells. Cells were 
seeded in a 24-well plate at a density of 1×10
4
 cells per well and allowed to attach for 12 h. 
Ac4ManAz or Ac3ManAz derivative (50 μM) was added and incubated with cells for 72 h. After 
washing with PBS, cells were incubated with DBCO-Cy5 (50 μM) for 1 h. Cells were lifted by 
incubating with trypsin solution and analyzed by flow cytometry. 
 
2.2.9 Comparison of passive and active cellular uptake of DBCO-Cy5. LS174T cells were 
seeded in a 24-well plate at a density of 1×10
4
 cells per well and allowed to attach for 12 h. 
Ac4ManAz (50 μM) was added to designated wells. After 72 h, non-treated cells were incubated 
with DBCO-Cy5 (50 μM) for 30 min, 1 h, and 2 h, respectively. Cells treated with Ac4ManAz 
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were incubated with DBCO-Cy5 (50 μM) for 1 h. After washing with PBS, cells were lifted by 
incubating with trypsin solution and analyzed by flow cytometry.  
 
2.2.10 Ac3ManAzNB mediated controlled cell labeling. LS174T cells were seeded onto 
coverslips in a 6-well plate at a density of 4×10
4
 cells per well and allowed to attach for 12 h. 
Ac3ManAzNB (50 μM) was added. After 4 h, UV light (10 mW/m
2
) was applied for 10 min, and 
the cells were further incubated for 68 h. Cells without UV irradiation were continuously 
incubated for 72 h. Cell samples for confocal imaging and flow cytometry were prepared 
following the abovementioned general procedures. 
 
2.2.11 Ac3ManAzBB mediated controlled cell labeling. LS174T cells were seeded onto 
coverslips in a 6-well plate with a cell density of 40 K/well. Ac3ManAzBB was added with a 
final concentration of 50 μM, followed by the addition of H2O2 with a final concentration of 200 
μM. The cells were incubated for 72 h. Cell samples for confocal imaging and flow cytometry 
were prepared following the abovementioned general procedures. 
 
2.2.12 Western blotting analysis of cells treated with azido-sugars. (1) Chemiluminescence 
method: azido-modified proteins in cell lysates were converted to biotinylated ones by 
incubating with phosphine-PEG3-biotin and then detected by streptavidin-HRP and ECL Western 
Blotting Substrate. (2) Fluorescence method: 20 μL of cell lysate was incubated with DBCO-Cy3 
(10 μM) in 5% bovine serum albumin (BSA) for 1 h. After gel running and membrane transfer, 
protein bands were visualized using an Image Quant LAS 4010 system with a Cy3/Cy3 
(excitation/emission) channel. 
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2.2.13 In vivo tumor labeling of Ac4ManAz, Ac3ManAzEt, and Ac3ManAzNB. LS174T colon 
tumors were established in 6 week-old female athymic nude mice by subcutaneous injection of 
LS174T cells (1.5×10
6
 cells) in Hank’s balanced salt solution (HBSS)/matrigel (1/1, v/v) into 
both flanks. When the tumors reached ~50 mm
3
, Ac4ManAz or Ac3ManAzEt or Ac3ManAzNB 
(25 mM, 20 μL) was injected into the left tumors once daily for three consecutive days while the 
same amount of PBS was injected to the right tumors as control (n=4 per group): (1) Tumors 
were harvested from mice (n=1 per group) at 24 h p.i. of azido-sugars and bisected. Half of the 
tumor was homogenized and lysed. The concentration of soluble proteins in cell lysates was 
determined by bicinchoninic acid (BCA) assay and adjusted to 5 mg/mL for each group. The rest 
of procedures were the same as the abovementioned western blotting analysis of cells. The other 
half of tumor was directly frozen in optimal cutting temperature (O.C.T.) compound and 
sectioned with a thickness of 8 μm. Tumor tissue sections were incubated with 5% BSA for 2 h 
and then labeled with DBCO-Cy5 (20 μM) for 30 min. After washing with PBS, DAPI (2 μg/mL) 
and CellMask orange plasma membrane stain (1 μg/mL) were added to stain cell nuclei and 
membrane, respectively. Tumor sections were imaged under a confocal laser scanning 
microscope. (2) In a separate study, at 24 h p.i. of azido-sugars, DBCO-Cy5 (5 mg/kg) was i.v. 
injected and its biodistribution was monitored using the Maestro In-Vivo Fluorescence Imaging 
System (n=3 per group). The excitation filter of 575-605 nm was used. Tumors and organs were 
harvested from mice at 24 h p.i. of DBCO-Cy5 and imaged ex vivo. Cy5 fluorescence intensity at 
selected regions of interest (ROIs) was quantified using the Maestro imaging software. After ex 
vivo imaging, tumors were bisected. Half of the tumor was directly frozen in O.C.T. compound, 
sectioned with a thickness of 8 μm, stained with DAPI (2 μg/mL) and CellMask orange plasma 
membrane stain (1 μg/mL), and imaged under a confocal laser scanning microscope. Organs and 
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the other half of tumors were homogenized and lysed. The lysates were measured on a 
fluorescence spectrometer to determine the amount of Cy5 retained in the tissues based on the 
standard curve of Cy5 fluorescence intensity. Data were presented as the percentage of injected 
dose per gram of tissue (% I.D./g). 
 
2.3 Results and Discussion 
To demonstrate whether replacing the C1-OAc of Ac4ManAz with an ether bond could 
inhibit its metabolic labeling activity, we first synthesized 1-ethoxy-3,4,6-triacetyl-N-
azidoacetylmannosamine (Ac3ManAzEt) with an ethyl ether bond at the C1 position (Fig. 2.1a) 
and investigated its cell labeling capability in vitro. LS174T colon cancer cells were incubated 
with Ac4ManAz, Ac3ManAzEt, and PBS, respectively, for three days, and the potentially 
expressed azido groups were detected by DBCO-Cy5 via Click chemistry. As shown in Fig. 2.1c, 
LS174T cells treated with Ac4ManAz showed strong Cy5 fluorescence intensity on the cell 
surface, indicating the successful expression of azido groups. In comparison, LS174T cells 
treated with Ac3ManAzEt or PBS showed negligible Cy5 fluorescence intensity on the cell 
surface, suggesting that Ac3ManAzEt failed to label cells with azido groups. Flow cytometry 
analysis of LS174T cells treated with Ac4ManAz also showed significantly enhanced Cy5 
fluorescence intensity compared to cells treated with Ac3ManAzEt or PBS (Fig. 2.1d). It is 
noteworthy that passively internalized DBCO-Cy5 was negligible compared to covalently 
attached DBCO-Cy5 in azido-modified LS174T cells (Supplementary Fig. 2.1). Western blotting 
analyses of LS174T cells treated with Ac4ManAz confirmed that azido groups were incorporated 
into multiple proteins, while LS174T cells treated with Ac3ManAzEt showed no azido-modified 
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proteins (Fig. 2.1e). These data demonstrated that Ac3ManAzEt with an ethyl ether bond at the 
C1 position failed to metabolically label LS174T cells with azido groups. 
 
To further demonstrate that the etherification of C1-OAc of Ac4ManAz was ascribed for the 
blocking effect and the cleavage of this ether bond to expose C1-OH would reactivate the 
labeling process, I synthesized 1-((2-nitrobenzyl)oxy)-3,4,6-triacetyl-N-azidoacetylmannosamine 
(Ac3ManAzNB) with an ultraviolet (UV)-cleavable 2-nitrobenzyl ether bond at the C1 position 
(Fig. 2.1b) and investigated its UV-controlled labeling capability in vitro. Ac3ManAzNB can be 
readily degraded into 3,4,6-triacetyl-N-azidoacetylmannosamine (Ac3ManAzOH) with the C1-
OH exposed upon UV irradiation. LS174T cells treated with Ac3ManAzNB (without UV 
irradiation) followed by reaction with DBCO-Cy5 showed negligible Cy5 attachment to cell 
surface, further demonstrating the blocking effect of etherification of C1-OAc (Fig. 2.1c). Upon 
UV treatment, LS174T cells treated with Ac3ManAzNB followed by reaction with DBCO-Cy5 
showed strong Cy5 fluorescence on the cell surface (Fig. 2.1c) as a result of the conversion of 
Ac3ManAzNB to Ac3ManAzOH which activated the labeling process (Fig. 2.1b). Flow 
cytometry and western blotting analyses also verified successful expression of azido groups in 
LS174T cells treated with Ac3ManAzNB+UV instead of Ac3ManAzNB-UV (without UV 
irradiation) (Fig. 2.1d-e). These experiments further demonstrated that etherification of C1-OAc 
of Ac4ManAz can block its metabolic labeling activity, which can be reactivated in the presence 
of a specific trigger that cleaves the ether bond to expose C1-OH. 
 
I next studied whether Ac3ManAzEt and Ac3ManAzNB show blocked metabolic labeling 
activity in vivo. Ac4ManAz, Ac3ManAzEt or Ac3ManAzNB was injected into implanted LS174T 
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tumor (left flank) in athymic nude mice once daily for three consecutive days, while PBS was 
injected into a contralaterally implanted LS174T tumor (right flank) as a control. Western 
blotting analysis of tumor tissues at 24 h post injection (p.i.) of azido-sugars showed a series of 
azido-modified proteins in tumors treated with Ac4ManAz while showed the same endogenous 
proteins in tumors treated with Ac3ManAzEt, Ac3ManAzNB and PBS (Supplementary Fig. 2.2), 
suggesting that Ac3ManAzEt and Ac3ManAzNB were unable to label LS174T tumors with azido 
groups in vivo. To understand how the expressed azido groups would improve the tumor 
accumulation of DBCO-cargo via in vivo Click chemistry, in a separate study, DBCO-Cy5 was 
intravenously (i.v.) injected at 24 h p.i. of azido-sugars and its biodistribution was monitored 
(Fig. 2.2a-b). At 48 h p.i. of DBCO-Cy5, Ac4ManAz-treated tumors showed a 5-fold Cy5 
fluorescence intensity compared to PBS-treated control tumors (Fig. 2.2c-d, Supplementary Fig. 
2.2). For Ac3ManAzEt and Ac3ManAzNB groups, no significant difference in Cy5 fluorescence 
intensity between the treated and control tumors was observed (Fig. 2.2c-d, Supplementary Fig. 
2.2). These experiments not only demonstrated the blocked metabolic activity of Ac3ManAzEt 
and Ac3ManAzNB in vivo but also indicated the excellent in vivo cancer targeting effect 
mediated by sugar labeling and Click chemistry. 
 
After demonstrating the controlled labeling strategy, I next aimed to apply it to in vivo 
cancer labeling and targeting. Since UV is not a practical trigger in vivo because of its poor tissue 
penetration and potential damage to healthy tissues,
14-16
 I aimed to develop Ac3ManAz 
derivatives that are responsive to internal cancer specific triggers such as redox dysregulation, 
elevated oxidant level, local hypoxia, and enzymes.
17-22
 However, different from UV irradiation 
which can cleave the 2-nitrobenzyl ether bond, these triggers are not able to directly cleave an 
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ether bond, thus requiring an incorporation of a self-immolative linker. Two conventional self-
immolative linkers, CL1 and CL2, have been widely used in prodrug designs (Scheme 2.2a).
23-26
 
Upon removal of the protecting group, CL1 can rapidly get rid of a CO2 molecule to yield the 
target alcohol structure. However, CL1 requires a carbonate bond which can be easily degraded 
by cellular esterases, and thus is not available for this design. CL2 can rapidly release the good 
leaving group, phenol structure, upon removal of the protecting group. Considering that the sugar 
structure might be a good leaving group due to the existence of the lactol structure, I designed 
PL1 (Scheme 2.2b) with a similar structure to CL2 and incorporate it into hydrogen peroxide 
(H2O2)-responsive Ac3ManAzHB (Fig. 2.3a).
27,28
 However, Ac3ManAzHB failed to release 
Ac3ManAzOH even though the protecting group was easily removed by H2O2 (Fig. 2.3b).  
 
I then designed PL2 with an additional phenyl group linked to the α-carbon of PL1 based on 
the assumption that the greatly stabilized degradation product will facilitate the self-immolative 
cleavage (Scheme 2.2c). To investigate the feasibility of PL2 as a self-immolative linker, H2O2-
responsive Ac3ManAzBB was synthesized and evaluated. Ac3ManAzBB succeeded in releasing 
the active Ac3ManAzOH in the presence of H2O2, as demonstrated by HPLC measurements (Fig. 
2.4) and ESI mass spectra. I then tested the controlled labeling capability of Ac3ManAzBB in 
LS174T colon cancer cells. After incubating with Ac3ManAzBB for 72 h and subsequently 
labeling with DBCO-Cy5 for 1 h, negligible Cy5 fluorescence was observed on the cell surface 
(lower panel, Fig. 2.5b). In the presence of H2O2, however, uniform Cy5 fluorescence was 
observed on the cell surface (upper panel, Fig. 2.5b), demonstrating H2O2-induced activation of 
the metabolic labeling process of Ac3ManAzBB. 
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I also developed several other trigger-activatable Ac3ManAz derivatives such as NQO1-
responsive Ac3ManAzHQ, hypoxia-responsive Ac3ManAzAB, and HDAC/CTSL responsive 
DCL-AAM using the same self-immolative linker, PL2 (Scheme 2.3). NQO1 was reported to be 
overexpressed in multiple colon cancers and other cancers.
29-31
 In the presence of the reducing 
agent, sodium dithionite, Ac3ManAzHQ underwent rapid degradation and eventually released 
metabolically active Ac3ManAzOH (Fig. 2.6), demonstrating its reduction-responsive property. 
In vitro cell labeling experiments showed that Ac3ManAzHQ well labeled NQO1-overexpressing 
LS174T colon cancer cells, while it failed to label IMR90 human fibroblast cells after incubation 
for three days. Tumor hypoxia is a common phenomenon in tumors when the fast growing tumor 
cells outgrow the blood supply and leave part of the tumor under hypoxia environment.
32-34
 In 
our design of hypoxia-responsive Ac3ManAzAB, the azo bond can be reduced to amine group by 
cellular azoreductase under hypoxia conditions, followed by the self-immolative cleavage to 
release the metabolically active Ac3ManAzOH. 
 
2.4 Conclusion 
I developed a controlled labeling strategy of azido-sugar precursors by chemical 
modification of the C1 site of Ac4ManAz with a trigger-removable ether bond. This controlled 
labeling strategy was demonstrated in vitro and in vivo using non-cleavable Ac3ManAzEt and 
UV-activatable Ac3ManAzNB. To apply this controlled labeling strategy to cancer targeting, I 
developed a new self-immolative linker (PL2) that can release the active sugar moiety in the 
presence of cancer-associated enzymes and further developed a library of trigger-activatable 
Ac3ManAz derivatives including NQO1-responsive Ac3ManAzHQ, hypoxia-responsive 
Ac3ManAzAB and HDAC/CTSL-responsive DCL-AAM. Meanwhile, I demonstrated that Click 
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chemistry could mediate excellent cancer targeting effect in vivo. I believe that the controlled 
labeling strategy reported here will provide a new perspective for the development of cancer 
targeted therapy. 
 
2.5 Figures and Schemes 
 
 
Scheme 2.1 Metabolic labeling processes of Ac4ManAz and trigger-activated labeling processes 
of dormant Ac3ManAz derivatives. P represents trigger-removable protecting group. 
 
 
 - 25 - 
 
Figure 2.1 Replacing the C1-OAc of Ac4ManAz with a cleavable ether bond enables controlled 
metabolic cell labeling in vitro. (a) Synthetic route of dormant Ac3ManAz derivatives including 
Ac3ManAzEt and UV-responsive Ac3ManAzNB. (b) Schematic illustration of UV irradiation-activated 
metabolic labeling of Ac3ManAzNB and subsequent detection of the expressed azido groups by DBCO-
Cy5 via Click chemistry. (c) CLSM images of LS174T colon cancer cells after incubated with Ac4ManAz 
(50 μM), Ac3ManAzEt (50 μM), Ac3ManAzNB (50 μM)-UV, Ac3ManAzNB (50 μM)+UV, and PBS, 
respectively, for 72 h and labeled with DBCO-Cy5 (50 μM, red) for 1 h. UV irradiation with an intensity 
of 10 mW/cm
2
 was applied for 10 min at the start of incubation. The cell nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI, blue). Scale bar: 10 μm. (d) Flow cytometry analysis of LS174T cells 
after treated with PBS, Ac4ManAz, Ac3ManAzEt, Ac3ManAzNB-UV, and Ac3ManAzNB+UV, 
respectively, for 72 h and labeled with DBCO-Cy5 for 1 h, following the same treatment conditions as 
described in (c). (e) Western blotting analysis of LS174T cells after treatment with Ac4ManAz, 
Ac3ManAzEt, Ac3ManAzNB+UV, Ac3ManAzNB-UV, and PBS, respectively, for 72 h, following the 
same treatment conditions as described in (c). Azido-modified proteins were biotinylated by incubating 
with phosphine-PEG4-biotin and then detected by streptavidin-horseradish peroxidase conjugate. 
Ac3ManAzEt, Ac3ManAzNB and PBS groups showed only two endogenous biotinylated protein bands. 
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Figure 2.2 Replacing the C1-OAc of Ac4ManAz with a cleavable ether bond enables 
controlled metabolic cell labeling in vivo. (a) Time frame of in vivo labeling study. Ac4ManAz, 
Ac3ManAzEt or Ac3ManAzNB (25 mM, 20 μL) was injected intratumorally (i.m.) to the left 
LS174T tumors of athymic nude mice once daily for three consecutive days (Day 1-3), and the 
right LS174T tumors were injected i.m. with PBS as controls. DBCO-Cy5 (5 mg/kg) was i.v. 
injected on Day 4. (b) In vivo whole body fluorescence imaging of mice from different groups at 
48 h p.i. of DBCO-Cy5. Tumors were shown by yellow arrows. (c) Ex vivo imaging of tissues 
harvested at 48 h p.i. of DBCO-Cy5. (d) Ex vivo fluorescence intensity of tumor tissues from (c). 
Data were presented as mean ± SEM (n=3) and analyzed by one-way ANOVA (Fisher; 0.01 < 
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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Scheme 2.2 (a) Two conventional self-immolative linkers (CL1 and CL2) used in prodrug 
systems. (b) Proposed linker 1 (PL1) derived from CL2. (c) Proposed linker 2 (PL2) modified 
from PL1. The additional benzene ring stabilize the cleaved product, thus facilitating the 
degradation process.   
 
 - 28 - 
 
Figure 2.3 (a) Synthetic route of Ac3ManAzHB with the incorporation of PL1. (b) Degradation 
of Ac3ManAzHB in the presence of H2O2, failing to release Ac3ManAzOH. 
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Figure 2.4 HPLC tracking of degradation of Ac3ManAzBB in the presence of H2O2. 
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Figure 2.5 (a) Schematic illustration of H2O2-activated metabolic labeling process. (b) CLSM 
images of LS174T cells after incubated with Ac3ManAzBB (50 μM) in the presence (upper row) 
or absence of H2O2 (lower row) for 72 h and subsequently labeled with DBCO-Cy5 (red) for 1 h. 
The cell nucleus was stained with DAPI (blue). Scale bar: 10 μm. 
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Scheme 2.3 Library of trigger-activatable Ac3ManAz derivatives. 
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Figure 2.6 (a) Degradation of Ac
3
ManAzHQ in the presence of Na
2
S
2
O
4
, as monitored by 
HPLC. (b) Proposed degradation mechanism of Ac
3
ManAzHQ in the presence of Na
2
S
2
O
4
. 
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Figure 2.7. (a) Schematic illustration of hNQO1-induced degradation of Ac
3
ManAzHQ into 
Ac
3
ManAzOH and activation of the metabolic labeling process. (b) CLSM images of hNQO1-
rich LS174T colon cancer cells, and hNQO1-deficient IMR-90 human fibroblast cells after 
treated with Ac
3
ManAzHQ (50 μM), Ac
3
ManAzHQ (50 μM) + Curcumin (50 μM), and PBS, 
respectively for three days, and labeled with DBCO-Cy5 (50 μM) for 1 h. Scale bar: 10 μm. (c) 
Average fluorescence intensity of different cell lines pretreated with Ac
3
ManAzHQ (50 μM), 
Ac
3
ManAzHQ (50 μM) + Curcumin (50 μM), and PBS, respectively. The Cy5 fluorescence 
intensity per cell was measured on a GE-analyzer. Data were presented as mean ± SEM and 
analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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Supplementary Figure 2.1. (a) Flow cytometry analyses of LS174T cells incubated with 
DBCO-Cy5 for 30 min, 1 h, and 2 h, respectively. Cells without DBCO-Cy5 treatment were used 
as negative control. Cells pretreated with Ac
4
ManAz (50 μM) for three days and further treated 
with DBCO-Cy5 for 1 h was used for comparison. (b) Mean fluorescence intensity of LS174T 
cells for different groups in (a). All of the data were presented as mean ± SEM and analyzed by 
one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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Supplementary Figure 2.2. Tumor accumulation of DBCO-Cy5 in Sugar-N3 (Ac4ManAz, 
Ac3ManAzEt, and Ac3ManAzNB) treated athymic nude mice. Sugar-N3 (25 mM, 20 μL) was 
injected to the left tumors once daily for three days, and the right tumors were injected with PBS 
as control. DBCO-Cy5 (5 mg/kg) was i.v. injected on Day 4 and its biodistribution was studied. 
(a) Picture of athymic nude mouse at 48 h p.i. of DBCO-Cy5. The left tumor pretreated with 
Ac4ManAz (25 mM, 20 μL) once daily for three days showed the intrinsic blue color of DBCO-
Cy5, and the right tumor as the control showed no blue color. A picture of DBCO-Cy5 solution 
was shown. (b) Ex vivo fluorescence intensity of tissues harvested from mice pretreated with 
Ac4ManAz, Ac3ManAzEt, and Ac3ManAzNB, respectively at 48 h p.i. of DBCO-Cy5. (c) CLSM 
images of tumor tissue sections at 48 h p.i. of DBCO-Cy5. The cell nucleus was stained with 
DAPI (blue). Scale bar: 20 μm. The parameters for confocal imaging were kept the same for all 
samples. (d) Retained Cy5 in tissues of Ac4ManAz, Ac3ManAzEt, and Ac3ManAzNB group 
mice, respectively at 48 h p.i. of DBCO-Cy5. All of the data were presented as mean ± SEM and 
analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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CHAPTER 3 
DCL-AAM MEDIATED CANCER-SELECTIVE LABELING 
 
 
3.1 Introduction 
As described in Chapter 2, I developed a library of trigger-activatable Ac3ManAz 
derivatives that can label cell types of interest in a trigger-dependent manner. These triggers can 
be either exogenous such as ultraviolet light or endogenous such as reductives, hydrogen 
peroxide, and enzymes.
1-3
 Compared to reductives and hydrogen peroxide, various enzymes are 
overexpressed in cancers and better represent the difference between cancer cells and normal 
cells.
4-7
 For example, both histone deacetylase (HDAC) and cathepsin L (CTSL) are reported 
over-expressed in cancer cell lines.
8-11
 To build an activatable Ac3ManAz derivative with high 
cancer-labeling specificity, 1-((4-(2,6-diacetamidohexanamido)phenyl)(phenyl)methoxy)-3,4,6-
triacetyl-N-azidoacetylmannosamine (histone deacetylase (HDAC)/cathepsin L (CTSL)-
responsive acetylated azidomannose, abbreviated as DCL-AAM) was designed by using N,N-
diacetyllysine as the enzyme-removable substrate, which can be serially cleaved by two separate 
cancer-overexpressing enzymes, HDAC and CTSL.
8, 9
 HDAC removes the N
6
-acetyl group of 
the lysine residue first, followed by the cleavage of the amide bond by CTSL.
12-14
 Such dual-
enzyme trigger design ensures improved cancer-specificity of DCL-AAM labeling. Upon 
removal of the HDAC/CTSL-responsive substrate, PL2 undergoes structural rearrangement to 
cleave off the highly conjugated 4-benzylidenecyclohexa-2,5-dien-1-imine and release the 
metabolically active Ac3ManAzOH (Scheme 3.1).  
 
3.2 Materials and Methods 
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3.2.1 Synthesis of DCL-AAM 
Synthesis of AcLys(NHS) (1). AcLys(OH) (2.0 mmol) and triethylamine (2.1 mmol) was 
dissolved in anhydrous DMF, followed by the addition of DCC (2.1 mmol) and NHS (2.1 mmol). 
The reaction mixture was stirred at room temperature for 24 h. The precipitate was filtered off, 
and the solvent was removed under reduced pressure. The crude product was directly used 
without further purification. 
Synthesis of (4-aminophenyl)(phenyl)methanol (2). 4-Aminobenzophenone (5.0 mmol) 
was dissolved in dry methanol, followed by addition of sodium borohydride (10.0 mmol). The 
mixture was stirred at room temperature for 24 h. After removal of the solvent, the crude product 
was purified by silica gel column chromatography using hexane/ethyl acetate (6/1 to 3/1) as the 
eluent. Compound 5 was obtained as a light yellow solid. 
1
H NMR (CDCl3, 500 MHz): δ (ppm) 
7.38 (d, 2H, Ph), 7.32 (t, 2H, Ph), 7.25 (t, 1H, Ph), 7.14 (d, 2H, Ph), 6.63 (d, 2H, Ph), 5.75 (s, 1H, 
CH(OH)), 3.65 (s, 1H, (CH(OH)), 3.45 (s, 2H, NH2). 
13
C NMR (CDCl3, 500 MHz): δ (ppm) 
146.1, 144.4, 134.4, 128.6, 128.2, 127.5, 126.6, 115.3, 76.2. ESI MS (m/z): calculated for 
C13H14NO [M+H]
+
 200.1, found 200.1. 
Synthesis of AcLys(DPM) (3). AcLys(NHS) (1.2 mmol) and compound 2 (1.2 mmol) were 
dissolved in anhydrous DMF, followed by the addition of triethylamine (1.2 mmol). The mixture 
was stirred at 40
o
C for 24 h. After removal of the solvent, the crude product was purified by 
silica gel column chromatography using ethyl acetate to ethyl acetate/methanol (20/1, v/v) as the 
eluent to yield a light yellow solid.
 1
H NMR (CD3OD, 500 MHz): δ (ppm) 7.50 (d, 2H, Ph), 7.34 
(d, 2H, Ph), 7.29 (m, 4H, Ph), 7.21 (t, 1H, Ph), 5.74 (s, 1H, CH(OH)), 4.39 (m, 1H, 
CHCH2CH2CH2CH2NHC(O)CH3), 3.15 (t, 2H, CHCH2CH2CH2CH2NHC(O)CH3), 2.00 (s, 3H, 
CHCH2CH2CH2CH2NHC(O)CH3), 1.89 (s, 3H, CHNHC(O)CH3), 1.83&1.72 (m, 2H, 
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CHCH2CH2CH2CH2NHC(O)CH3), 1.53 (m, 2H, CHCH2CH2CH2CH2NHC(O)CH3), 1.41 (m, 2H, 
CHCH2CH2CH2CH2NHC(O)CH3). 
13
C NMR (CD3OD, 500 MHz): 172.2, 172.0, 171.7, 144.7, 
140.9, 137.3, 128.1, 127.0, 126.5, 120.1, 75.3, 54.4, 38.9, 31.7, 28.9, 23.1, 21.4, 21.2. ESI MS 
(m/z): calculated for C23H29N3O4Na [M+Na]
+
 434.2, found 434.2. 
Synthesis of AcLys(DPM-CNCCl3) (4). Compound 3 (0.5 mmol) and CNCCl3 (5.0 mmol) 
were dissolved in anhydrous THF, followed by the addition of 1,8-diazabicycloundec-7-ene 
(DBU, 0.5 mmol). The reaction mixture was stirred at room temperature for 4 h. After removal 
of the solvent, the crude product was purified by silica gel column chromatography to yield a 
white solid. 
Synthesis of compound Ac3ManAzOH (5). Ac4ManAz (0.5 mmol) and ammonium 
carbonate (0.75 mmol) were dissolved in THF/methanol (2/1, v/v) and stirred at room 
temperature. After 12 h, the solvent was removed and the crude product was purified by silica 
gel column chromatography to yield a white solid. 
Synthesis of DCL-AAM. Ac3ManAzOH (0.2 mmol) and AcLys(DPM-CNCCl3) (0.22 mmol) 
were dissolved in anhydrous acetonitrile, followed by the addition of boron trifluoride etherate 
(2.0 mmol). The mixture was stirred at 0
o
C for 1 h. After removal of the solvent, the crude 
product was purified by silica gel column chromatography and HPLC to yield a white solid. 
1
H 
NMR (CDCl3, 500 MHz): δ (ppm) 7.55 (d, 2H, Ph), 7.35-7.28 (m, 7H, Ph), 6.56 (d, 1H, 
CH3C(O)NHCH), 6.46 (d, 1H, CH2C(O)NHCH), 5.77 (t, 1H, CH3C(O)NHCH2), 5.65 (s, 1H, 
PhCH), 5.38 (ddd, 1H, CH2CHCHCH), 5.17 (ddd, 1H, CH2CHCHCH), 4.80&4.77 (1H, 
NHCHCHO), 4.68 (m, 1H, NHCHCHO), 4.48 (m, 1H, CHCH2CH2CH2CH2NHC(O)CH3), 
4.18&3.99 (m, 2H, CH2CHCHCH), 4.05 (m, 2H, COCH2N3), 3.94 (m, 1H, CH2CHCHCH), 
3.35&3.23 (m, 2H, CHCH2CH2CH2CH2NHC(O)CH3), 2.13&2.07&2.03&2.00 (s, 15H, 
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CH3C(O)O), 1.77 (m, 2H, CHCH2CH2CH2CH2NHC(O)CH3), 1.57 (m, 2H, 
CHCH2CH2CH2CH2NHC(O)CH3), 1.41 (m, 2H, CHCH2CH2CH2CH2NHC(O)CH3). ESI MS 
(m/z): calculated for C37H48N7O12 [M+H]
+
 782.3, found 782.3. 
 
3.2.2 Synthesis of HDAC/CTSL fluorescent reporter (Naph-Lys) 
Synthesis of Naph-NH2. 4-Amino-1,8-naphthalic anhydride (10 mmol) was dissolved in 
ethanol (100 mL) under nitrogen atmosphere and brought to reflux. 1-butylamine (15 mmol) was 
then added and the mixture was further refluxed for 8 h. After cooling down, the solvent was 
removed under reduced pressure, and the crude product was purified by silica gel column 
chromatography using DCM/ethyl acetate (2/1, v/v) as the eluent.  
1
H NMR (CDCl3, 500 MHz): 
δ (ppm) 8.60 (d, 1H, C(O)CCHCHCH), 8.42 (d, 1H, C(O)CCHCHCH), 8.10 (d, 1H 
C(O)CCHCHCH), 7.66 (t, 1H, C(O)CCHCH), 6.89 (d, 1H, C(O)CCHCH), 4.94 (s, 2H, NH2), 
4.18 (t, 2H, CH2CH2CH2CH3), 1.71 (m, 2H, CH2CH2CH2CH3), 1.45 (m, 2H, CH2CH2CH2CH3), 
0.97 (s, 3H, CH2CH2CH2CH3). ESI MS (m/z): calculated for C16H17N2O4 [M+H]
+
 269.1, found 
269.1. 
Synthesis of Naph-Lys. Naph-NH2 (1.0 mmol) and AcLys(OH) (1.0 mmol) were dissolved 
in DMF, followed by the addition of DCC (1.1 mmol), NHS (1.1 mmol), and triethylamine (1.0 
mmol). The mixture was stirred at 45
o
C for 48 h. After removal of precipitate and solvent, the 
crude product was purified by silica gel column chromatography to yield a yellow solid. 
1
H 
NMR (CD3OD, 500 MHz): δ (ppm) 8.57 (dd, 1H, C(O)CCHCHCH), 8.52 (d, 1H C(O)CCHCH), 
8.51 (dd, 1H, C(O)CCHCHCH), 8.12 (dd, 1H, C(O)CCHCH), 7.84 (dd, 1H, C(O)CCHCHCH), 
4.62 (dd, 1H, CHCH2CH2CH2CH2), 4.14 (t, 2H, CH2CH2CH2CH3), 3.22 (t, 2H, 
CHCH2CH2CH2CH2), 2.06 (s, 3H, CH3C(O)NHCH), 1.98 (m, 2H, CHCH2CH2CH2CH2), 1.92 (s, 
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3H, CH3C(O)NHCH2), 1.69 (m, 2H, CH2CH2CH2CH3), 1.60 (m, 2H, CHCH2CH2CH2CH2), 1.53 
(m, 2H, CHCH2CH2CH2CH2), 1.43 (m, 2H, CH2CH2CH2CH3),  0.99 (m, 3H, CH2CH2CH2CH3). 
ESI MS (m/z): calculated for C26H33N4O5 [M+H]
+
 481.2, found 481.2. 
 
3.2.3 Detection of cellular HDAC/CTSL activity. Cells were seeded in a 24-well plate at a 
density of 10k cells per well and allowed to attach overnight. Naph-Lys (50 μM) was added and 
incubated with cells for different time (0.5, 1, 2, and 4 h). Cells were then washed, fixed with 4% 
PFA, and stained with DAPI. Average fluorescence intensity of cells was measured on the IN 
Cell Analyzer 2200. The DAPI and FITC channels were used for determining the number of 
cells per well and the total fluorescence intensity of released Naph-NH2 per well, respectively. 
Data were presented as the mean fluorescence intensity ± SEM per cell (n = 6). 
 
3.2.4 Inhibitory effect of TSA and Z-FY-CHO on cellular HDAC/CTSL activity. Cells were 
seeded in a 24-well plate at a density of 10k cells per well and allowed to attach overnight. The 
cells were incubated with Naph-Lys (50 μM), Naph-Lys (50 μM) + TSA (1 μM), Naph-Lys (50 
μM) + Z-FY-CHO (50 μM), and PBS, respectively, for 4 h, fixed with 4% PFA, and stained with 
DAPI. Average fluorescence intensity of cells was measured on the IN Cell Analyzer 2200 using 
DAPI and FITC channels.  
 
3.2.5 DCL-AAM mediated controlled cell labeling in vitro. Cells were seeded onto coverslips in 
a 6-well plate at a density of 40k cells per well and allowed to attach overnight. The cells were 
incubated with DCL-AAM (50 μM), DCL-AAM (50 μM) + TSA (1 μM), DCL-AAM (50 μM) + 
Z-FY-CHO (50 μM), and PBS, respectively, for 72 h and subsequently labeled with DBCO-Cy5 
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(50 μM) for 1 h. Cell samples for confocal imaging and IN Cell Analyzer 2200 measurements 
were prepared following the abovementioned procedures. 
 
3.2.6 Western blotting analysis of DCL-AAM treated cells. Cells were seeded onto cell culture 
flasks (25 cm
2
 growth area) at a density of 500k cells per flask and allowed to attach overnight. 
The cells were then treated with DCL-AAM (50 μM), DCL-AAM (50 μM) + TSA (1 μM), DCL-
AAM (50 μM) + Z-FY-CHO (50 μM), and PBS, respectively, for 72 h. Western blotting analysis 
of cells were conducted following the procedures described in Chapter 2. 
 
3.2.7 DCL-AAM mediated cancer-selective labeling in vivo: (1) Western blotting method: 
LS174T tumor models were established in 6 week-old female athymic nude mice by 
subcutaneous injection of LS174T colon cancer cells (1.5 × 10
6 
cells) in HBSS/matrigel (1/1, 
v/v). When the tumors reached ~50 mm
3
, DCL-AAM (60 mg/kg, 1.0 molar equivalent of azido 
groups) was i.v. injected once daily for three consecutive days. Mice i.v. administered with 
Ac4ManAz (40 mg/kg, 1.2 molar equivalent of azido groups) or PBS were used as controls. At 
24 h post the last injection, tumors and organs were harvested for western blotting analyses 
following the abovementioned procedures. Azido-labeled proteins were visualized using the 
fluorescence method. (2) Fluorescence imaging method: in a separate study, at 24 h post the last 
injection of DCL-AAM or Ac4ManAz or PBS, DBCO-Cy5 (10 mg/kg) was i.v. injected and its 
biodistribution was monitored using the Bruker In-Vivo Xtreme Imaging System. The 
excitation/emission filter of 630 nm/700 nm was used. Tumors and organs were harvested from 
mice at 48 h p.i. of DBCO-Cy5 and imaged ex vivo. Fluorescence intensity at selected ROIs was 
quantified using the Bruker imaging software. After ex vivo imaging, tumors were bisected. Half 
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of the tumor was directly frozen in O.C.T. compound, sectioned with a thickness of 8 μm, 
stained with DAPI (2 μg/mL) and CellMask orange plasma membrane stain (1 μg/mL), and 
imaged under a confocal laser scanning microscope. Organs and the other half of tumors were 
homogenized and lysed. The lysates were measured on a fluorescence spectrometer to determine 
the amount of Cy5 retained in the tissues. Data were presented as % I.D./g. 
 
3.2.8 Tumor labeling kinetics of DCL-AAM in vivo. Athymic nude mice bearing subcutaneous 
LS174T tumors were i.v. injected with DCL-AAM (60 mg/kg). Mice without DCL-AAM 
injection were used as controls. At different time (8, 24, and 48 h) p.i. of DCL-AAM, tumors 
were harvested, frozen in O.C.T. compound, and sectioned with a thickness of 8 μm. Tumor 
tissue sections were incubated with 5% BSA for 2 h and then labeled with DBCO-Cy5 (20 μM) 
for 30 min. After washing with PBS, DAPI (2 μg/mL) and CellMask orange plasma membrane 
stain (1 μg/mL) were added to stain cell nuclei and membrane, respectively. Tumor tissue 
sections were imaged under a confocal laser scanning microscope. The imaging parameters were 
kept the same for all samples imaged. Data analyses were performed with the ZEN 2011 
software. The mean Cy5 fluorescence intensity of each image was extracted and averaged over 
20 images to obtain the mean Cy5 fluorescence intensity of each tissue section, which was then 
averaged over 20 tissue sections to obtain the mean Cy5 fluorescence intensity for each tumor. 
 
3.2.9 Dose frequency-dependent DCL-AAM mediated tumor labeling in vivo. Athymic nude 
mice (n=3 per group) bearing subcutaneous LS174T tumors were i.v. administered with DCL-
AAM (60 mg/kg) for different times (one, two, or three injections) with a 24 h interval. Mice 
without DCL-AAM injection were used as controls. At 24 h post the last injection of DCL-AAM, 
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tumors were harvested, frozen in O.C.T. compound, and sectioned. Tumor tissue sections were 
stained, imaged, and analyzed following the procedures described in 3.2.8. 
 
3.3 Results and Discussion ` 
HDAC/CTSL activity in different cell lines was detected using a fluorescence turn-on 
reporter, Naph-Lys, which shares the same HDAC/CTSL-removable substrate with DCL-AAM 
(Fig. 3.1a-b). All tested cancer cell lines including HeLa cell, LS174T colon cancer cell, MCF-7 
breast cancer cell, HepG2 liver cancer cell, and 4T1 and MDA-MB-231 triple-negative breast 
cancer (TNBC) cells showed much higher HDAC/CTSL activity than non-cancerous cell lines 
such as MCF-10A breast basal epithelial cell, HBEC-5i cerebral microvascular endothelium cell, 
and IMR-90 human fibroblast cell (Fig. 3.1c-d). In the presence of the inhibitor for either HDAC 
(Trichostatin A (TSA)) or CTSL (Z-FY-CHO),
12
 turn-on fluorescence intensity of Naph-Lys 
greatly decreased as a result of the reduced enzymatic activity (Fig. 3.1d).  
 
The controlled labeling capability of DCL-AAM in vitro was studied by incubating different 
cell lines with DCL-AAM for three days and subsequently detecting the expressed azido groups 
using DBCO-Cy5. CLSM images showed strong Cy5 fluorescence intensity on the surface of 
LS174T and 4T1 cells (Fig. 3.2a), in sharp contrast to the negligible Cy5 fluorescence intensity 
observed on the surface of MCF-10A cells (Fig. 3.2b), indicating the selective labeling capability 
of DCL-AAM in cancer cells with high HDAC/CTSL activity over normal cells with low 
HDAC/CTSL activity. The labeling efficiency of DCL-AAM in cancer cells was significantly 
reduced in the presence of TSA or Z-FY-CHO (Fig. 3.2a, c), substantiating HDAC/CTSL 
induced activation of DCL-AAM for metabolic labeling. Western blotting analysis of LS174T 
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cells treated with DCL-AAM, DCL-AAM+TSA, and DCL-AAM+Z-FY-CHO, respectively, also 
verified the inhibitory effect of TSA and Z-FY-CHO against the metabolic activity of DCL-
AAM (Fig. 3.2d).  
 
We next studied the cancer-selective labeling capability of DCL-AAM in vivo. DCL-AAM 
was i.v. injected into athymic nude mice bearing LS174T tumors once daily for three consecutive 
days. Mice treated with Ac4ManAz and PBS were used as controls. Western blotting analyses of 
tumor tissues at 24 h p.i. of azido-sugars showed an increase in the amount of azido-modified 
proteins in DCL-AAM group compared to PBS group, while negligible difference in the amount 
of azido-modified proteins in liver, spleen, heart, and lung was observed between DCL-AAM 
and PBS groups (Fig. 3.3a-b). In contrast, Ac4ManAz with no labeling selectivity showed non-
specific labeling in normal tissues, with a considerable amount of azido groups expressed in liver, 
spleen, lung, and kidney tissues (Fig. 3.3b). These experiments demonstrated the superior 
cancer-selective labeling capability of DCL-AAM in vivo in comparison with Ac4ManAz. In a 
separate study, DBCO-Cy5 was i.v. injected at 24 h post azido-sugar injections and its 
biodistribution was monitored. At 48 h p.i. of DBCO-Cy5, tumors in DCL-AAM and AAM 
groups showed significantly enhanced Cy5 retention than in PBS group (Fig. 3.3c). Imaging of 
the harvested tumors in DCL-AAM group showed a 1.5-fold Cy5 fluorescence intensity 
compared to PBS group (Fig. 3.3d-e), while Cy5 retention in liver, spleen, heart, lung, and 
kidney was non-significantly changed (Fig. 3.3d-e). Mice treated with Ac4ManAz, however, 
showed significantly enhanced accumulation of DBCO-Cy5 in liver and lung compared to 
control mice treated with PBS (Fig. 3.3c-e). Compared to Ac4ManAz group, DBCO-Cy5 in 
DCL-AAM group showed improved accumulation in tumor but reduced accumulation in liver 
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and lung (Fig. 3.3d-e). Together, these experiments demonstrated that DCL-AAM was able to 
selectively label LS174T tumors in vivo and that the expressed azido groups could significantly 
enhance the tumor accumulation of DBCO-Cy5 via Click chemistry.  
 
The tumor labeling kinetics of DCL-AAM in vivo was studied to better understand DCL-
AAM mediated cancer labeling. DCL-AAM was i.v. injected into LS174T tumor-bearing nude 
mice, and the tumors were harvested and sectioned at 8, 24, and 48 h p.i., respectively. 
Metabolically expressed azido groups in tumor tissues were detected by staining with DBCO-
Cy5. Tumor tissues harvested at 8 h p.i. of DCL-AAM showed significantly enhanced Cy5 
fluorescence intensity on the cell surface compared to the control group without DCL-AAM 
treatment (Fig. 3.3f-g, Supplementary Fig. 3.1b), indicating that DCL-AAM successfully labeled 
tumor cells with azido groups. The amount of expressed azido groups in tumors significantly 
increased over the course of 24 h treatment with DCL-AAM (Fig. 3.3f-g). No significant 
difference in the amount of expressed azido groups between 24 h and 48 h groups was observed, 
indicating the metabolic labeling process of DCL-AAM was largely complete within 24 h (Fig. 
3.3f-g). Dose escalation through multiple injections of DCL-AAM (24 h interval) resulted in 
nearly linear increase of the amount of expressed azido groups in tumor tissues (Fig. 3.3h-i, 
Supplementary Fig. 3.1d).  
 
3.4 Conclusion 
I addressed the main challenge of tissue-selective labeling via rational chemical design of 
cell-labeling sugar precursors and developed DCL-AAM, a HDAC/CTSL-activatable Ac3ManAz 
derivative that can selectively label a wide range of cancer cells over normal cells in vitro and in 
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vivo. DCL-AAM mediated labeling of cancer cells in vitro was achieved by directly incubating 
cells with DCL-AAM. The in vivo distribution and metabolic labeling process of DCL-AAM in 
tumor tissues largely finish within 24 h post injection, evidenced by the time course labeling 
studies which showed statistically non-significant change of amount of expressed azido groups 
between 24 and 48 h post DCL-AAM administration (Fig. 3.3f-g). Dose escalation of DCL-
AAM can result in the increase of azido expression in tumor tissues (Fig. 3.3h-i), and the studies 
to investigate the up limit of azido concentration in tumor tissues for optimal targeting are 
underway. The substantively greater density of azido groups that can be installed on the surface 
of cancer cells by DCL-AAM in comparison with the endogenous expression of conventional 
protein receptors can potentially impart much greater efficiency for cancer targeting.  
 
3.5 Figures and Schemes 
 
 
Scheme 3.1 Schematic illustration of HDAC/CTSL-induced degradation of DCL-AAM. HDAC 
removes the N
6
-acetyl group of the lysine residue first, followed by cleavage of the amide bond 
by CTSL and self-cleavage of PL2 to release Ac3ManAzOH. 
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Scheme 3.2. Synthetic route of HDAC/CTSL responsive DCL-AAM 
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Scheme 3.3. Synthetic route of HDAC/CTSL fluorescent reporter (Naph-Lys) 
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Figure 3.1. HDAC and CTSL are overexpressed in various cancer cell lines. (a) Structure of 
the HDAC/CTSL fluorescence turn-on reporter (Naph-Lys) and its degradation product (Naph-
NH2) in the presence of HDAC/CTSL. (b) Excitation and emission spectra of Naph-Lys (5 
μg/mL in methanol) and Naph-NH2 (200 ng/mL in methanol). (c) Detection of HDAC/CTSL 
activity in different cell lines (HeLa, black; LS174T, red; MCF-7, blue; 4T1, magenta; HepG2, 
olive; MDA-MB-231, navy; MCF-10A, violet; HBEC-5i, purple; IMR-90, orange). (d) Average 
fluorescence intensity of different cell lines treated with Naph-Lys (50 μM), Naph-Lys (50 μM) 
+ TSA (1 μM), and Naph-Lys (50 μM) + Z-FY-CHO (50 μM), respectively, for 4 h. Data were 
presented as mean ± SEM (n=6) and analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; 
**P ≤ 0.01; ***P ≤ 0.001). 
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Figure 3.2. DCL-AAM mediated cancer-selective labeling in vitro. (a) CLSM images of 
LS174T and 4T1 cells after incubated with DCL-AAM (50 μM), DCL-AAM (50 μM)+TSA (1 
μM, inhibitor of HDAC), and DCL-AAM (50 μM)+Z-FY-CHO (50 μM, inhibitor of CTSL), 
respectively, for 72 h and labeled with DBCO-Cy5 (50 μM, red) for 1 h. The cell nuclei were 
stained with DAPI (blue). Scale bar: 10 μm. (b) CLSM images of MCF-10A breast basal 
epithelial cells (the control cell line) after incubated with DCL-AAM (50 μM) or PBS for 72 h 
and labeled with DBCO-Cy5 (50 μM) for 1 h. The cell nuclei were stained with DAPI. Scale bar: 
10 μm. (c) Average Cy5 fluorescence intensity of different cell lines (LS174T, 4T1, and MCF-
10A cells), following the same treatment as described in (a) and (b). Data were presented as 
mean ± SEM (n=6) and analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; 
***P ≤ 0.001). (d) Western blotting analysis of LS174T cells after treated with DCL-AAM, 
DCL-AAM+TSA, and DCL-AAM+Z-FY-CHO, respectively, for 72 h. Cell lysates were 
incubated with DBCO-Cy3 for 1 h at 37
o
C prior to gel running. Protein bands were visualized 
using ImageQuant LAS 4010 system. 
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Figure 3.3. DCL-AAM mediated cancer-selective labeling in vivo. (a) Time frame of in vivo labeling 
study. DCL-AAM (60 mg/kg), Ac4ManAz (40 mg/kg) or PBS was i.v. injected into athymic nude mice 
bearing subcutaneous LS174T tumors once daily for three days. At 24 h post the last injection, the 
metabolic expression of azido groups in tumor tissues was analyzed by western blotting (b) or by 
monitoring the biodistribution of i.v. injected DBCO-Cy5 (10 mg/kg) (c-e). (b) Western blotting analysis 
of tissues harvested from mice treated with Ac4ManAz, DCL-AAM, and PBS, respectively. Tissue lysates 
were incubated with DBCO-Cy3 for 1 h at 37
o
C prior to gel running. (c) In vivo whole body fluorescence 
imaging of mice treated with DCL-AAM, Ac4ManAz, and PBS, respectively, at 48 h p.i. of DBCO-Cy5. 
Tumors were shown by yellow arrows. (d) Ex vivo fluorescence imaging of tissues harvested at 48 h p.i. 
of DBCO-Cy5. (e) Average Cy5 fluorescence intensity of tissues (n=3) from (d). (f-g): Athymic nude 
mice bearing subcutaneous LS174T tumors (n=3) were i.v. injected with DCL-AAM (60 mg/kg). Tumors 
were harvested and sectioned at 8, 24, and 48 h p.i. of DCL-AAM, respectively, for determining the time-
course expression profiles of azido groups. Tumor tissue sections were labeled with DBCO-Cy5 for 30 
min. (f) CLSM images of tumor tissues harvested from mice at 8, 24, and 48 h p.i. of DCL-AAM, 
respectively. Scale bar: 10 μm. (g) Normalized Cy5 fluorescence intensity of tumor tissues (n=20) from 
(f). (h-i): Athymic nude mice bearing subcutaneous LS174T tumors were i.v. administered with 0, 1, 2, 
and 3 injections of DCL-AAM (60 mg/kg, 24 h interval), respectively, and tumors were harvested and 
sectioned at 24 h post the last injection of DCL-AAM for determining the dose-escalated expression 
profiles of azido groups. (h) CLSM images of tumor tissues harvested from mice with 2 and 3 injections 
of DCL-AAM, respectively. Scale bar: 10 μm. (i) Normalized Cy5 fluorescence intensity of tumor tissues 
(n=20) from (g). All the numerical data were presented as mean ± SEM and analyzed by one-way 
ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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Supplementary Figure 3.1. DCL-AAM mediated tumor labeling in vivo was time- and dose 
frequency-dependent. (a-b) In vivo tumor labeling kinetics of DCL-AAM. (a) Time frame of in 
vivo labeling kinetics study. Athymic nude mice bearing subcutaneous LS174T tumors were i.v. 
injected with DCL-AAM (60 mg/kg). Tumors were harvested and sectioned at 8, 24, and 48 h p.i. 
of DCL-AAM, respectively, for determining the time-course expression profiles of azido groups. 
(b) CLSM images of tumor tissue sections harvested at 8, 24, and 48 h p.i. of DCL-AAM (60 
mg/kg), respectively. Tumor tissue sections were blocked with 5% BSA for 2 h and then labeled 
with DBCO-Cy5 (red) for 30 min. Cell nuclei and membrane were stained with DAPI (blue) and 
CellMask orange plasma membrane stain (green), respectively. Scale bar: 10 μm. (c-d) Dose 
frequency-dependent DCL-AAM mediated tumor labeling in vivo. (c) Time frame of in vivo 
labeling study. Athymic nude mice bearing subcutaneous LS174T tumors were i.v. administered 
with DCL-AAM (60 mg/kg) for once, twice, and three times, respectively. Tumors were 
harvested and sectioned at 24 h post the last injection of DCL-AAM. (d) CLSM images of tumor 
tissue sections harvested from athymic nude mice with 0, 1, 2, and 3 injections of DCL-AAM, 
respectively. Scale bar: 10 μm. 
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CHAPTER 4 
ATTACK THERAPY FOR CANCER TREATMENT 
 
4.1 Introduction 
After demonstrating the superior cancer-selective labeling capability of DCL-AAM and the 
resulting excellent targeting effect of DBCO-Cy5 via Click chemistry, I next aimed to develop 
active tissue targeting via anchored Click chemistry (ATTACK, Scheme 4.1), an unprecedented 
in vivo targeting technology by combining DCL-AAM mediated tissue-selective labeling and 
efficient Click chemistry. In the first step, DCL-AAM was i.v. injected to metabolically label 
cancer cells with azido group, followed by the targeting of DBCO-therapeutic agents via Click 
chemistry in the second step. In principle, ATTACK cancer-targeting strategy applies to all 
DBCO-functionalized anticancer drugs or nanomedicines. Modification of anticancer drugs or 
nanomedicines with DBCO group can be easily achieved, without significant changes in the size, 
morphology, and other physiological properties, which are advantageous over conventional 
protein-based targeting ligands.
1-4
 The substantively greater density of azido group (10
7
/cell) that 
can be installed on the surface of cancer cells by DCL-AAM in comparison with the endogenous 
expression of conventional protein receptors (10
3
-10
5
/cell) can also potentially impart much 
greater efficiency for cancer targeting.
5, 6
 
 
Triple-negative breast cancer (TNBC), characterized by the limited expression of estrogen 
receptors, progesterone receptors, and epidermal growth factor receptor 2 (HER2), has nullified 
the vast majority of targeted therapies and is one of the most difficult types of tumors to treat in 
clinic.
7-10
 It is well known that there is a lack of efficient targeted therapies for the treatment of 
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TNBCs due to the absence of characteristic cell-surface receptors
11
, however, DCL-AAM 
mediated labeling followed by targeting of DBCO-drug conjugate may circumvent this limitation 
because of its independence of endogenous receptor expressions. Besides TNBCs, ATTACK 
therapy via the combination of DCL-AAM and DBCO-drug conjugates also has great potential 
for the targeted treatment of other cancers and diseases devoid of unique extracellular 
biomarkers. In this study, I used DCL-AAM and cathepsin-B degradable DBCO-doxorubicin 
conjugate (DBCO-VC-Dox) as substrates to evaluate the targeting effect and therapeutic benefits 
of ATTACK therapy in multiple tumor models including primary LS174T colon tumor and 
MDA-MB-231 TNBC. 
 
4.2 Materials and Methods 
4.2.1 Synthesis of DBCO-VC-Dox. Doxorubicin hydrochloride (0.05 mmol), Fmoc-Val-Cit-
PAB-PNP (0.05 mmol) and triethylamine (0.06 mmol) were dissolved in dimethylformamide 
and stirred at 40
o
C for 12 h, at which point diisopropylethylamine (100 μL) was added. After 12 
h, DBCO-PEG1k-NHS (0.05 mmol) was added and the mixture was stirred at 40
o
C for another 24 
h. The reaction solution was precipitated into diethyl ether to yield a red solid, which was 
purified by dialysis (1k cut-off molecular weight) for 48 h. 
 
4.2.2 Cathepsin B-induced degradation of DBCO-VC-Dox. Bovine spleen cathepsin B was 
activated following the reported procedures.
12
 DBCO-VC-Dox was added to the activated 
cathepsin B solution and incubated at 37
o
C. Aliquots of the mixture were taken out for HPLC 
measurements at selected time points. 
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4.2.3 Uptake of DBCO-VC-Dox in DCL-AAM-treated cancer cells. Cells were seeded in a 24-
well plate at a density of 10k cells per well and incubated with DCL-AAM (50 μM) or PBS for 
three days. After washing, cells were incubated with DBCO-VC-Dox (20 μM) for different time 
(0.5, 1, 2, and 4 h), lysed, and measured on a plate reader for fluorescence intensity. After 
fluorescence measurements, protein concentration in each well was determined via BCA assay. 
The final data were presented as fluorescence intensity of DBCO-VC-Dox per milligram protein. 
 
4.2.4 Uptake mechanism of DBCO-Cy5 in DCL-AAM treated cells. LS174T cells were seeded 
onto cell culture dishes with cover glass bottom and incubated with DCL-AAM (50 μM) for 
three days. After washing with PBS, the cells were incubated with DBCO-Cy5 (20 μM) and 
lysotracker green (2 μg/mL) for 1 h. Hoechst 33342 (10 μg/mL) and CellMask orange plasma 
membrane stain (1 μg/mL) were then added to stain cell nuclei and membrane, respectively, for 
10 min. After washing with PBS, the cells were further incubated in fresh medium at 37
o
C for 
different time (1, 3, 6, 12, and 24 h) before being imaged under a fluorescence microscope to 
monitor the cellular internalization of DBCO-Cy5.  
 
4.2.5 Pharmacokinetics study of DBCO-VC-Dox. DBCO-VC-Dox (5 mg/kg in Dox equivalent) 
was i.v. injected into female athymic nude mice (n=3). At selected time points (10 min, 30 min, 1 
h, 2 h, 4 h, 6 h, 12 h, and 24 h p.i.), blood was collected from orbital sinus using capillary tubes 
and diluted with methanol/H2O. After centrifugation, the supernatant was transferred to a black 
96-well plate for fluorescence measurement on a plate reader. A gradient concentration of 
DBCO-VC-Dox was used for determining the standard curve. The plasma concentration of 
DBCO-VC-Dox was calculated in μg/mL. 
 - 60 - 
4.2.6 Short-term efficacy study of DCL-AAM+DBCO-VC-Dox against subcutaneous LS174T 
tumors. LS174T tumors were established in 6 week-old female athymic nude mice by 
subcutaneous injection of LS174T colon cancer cells (1.5×10
6
 cells) in HBSS/matrigel (1/1, v/v, 
50 μL) into both flanks. When the tumors reached ~50 mm3, mice were randomly divided into 4 
groups (group 1: DCL-AAM+DBCO-VC-Dox; group 2: DBCO-VC-Dox; group 3: DCL-AAM; 
group 4: PBS; n = 3). For group 1 and group 3, DCL-AAM (60 mg/kg) was i.v. injected once 
daily for three days (Day 0, 1, and 2). Mice in the other two groups were i.v. injected with PBS 
as control. At 24 h post the last injection of DCL-AAM, DBCO-VC-Dox (10 mg/kg in Dox 
equivalent) or PBS was i.v. injected. At 48 h p.i., tumors were harvested and bisected. Half of the 
tumors were frozen with O.C.T. compound, sectioned with a thickness of 8 μm, and analyzed for 
apoptosis via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. 
Organs and the other half of tumors were weighed, homogenized, and lysed. After the addition of 
acidified isopropanol, the mixture was vortexed and frozen overnight at -20
o
C. After 
centrifugation, the supernatant was measured on a fluorescence spectrometer to determine the 
retained Dox in tissues. Data were presented as %I.D./g. 
 
4.2.7 Long-term efficacy study of DCL-AAM+DBCO-VC-Dox against subcutaneous LS174T 
tumors. LS174T tumors were established in 6 week-old female athymic nude mice by 
subcutaneous injection of LS174T cells (1.5×10
6
 cells in HBSS/matrigel (1/1, v/v, 50 μL)) into 
both flanks. When the tumors reached ~50 mm
3
, mice were randomly divided into 4 groups 
(group 1: DCL-AAM+DBCO-VC-Dox; group 2: DBCO-VC-Dox; group 3: DCL-AAM; group 4: 
PBS; n = 5). For group 1 and group 3 mice, DCL-AAM (60 mg/kg) was i.v. injected on Day 0, 1, 
2, 15, and 16. Mice in the other two groups were i.v. injected with PBS as control. DBCO-VC-
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Dox (12 mg/kg (first three injections) or 8 mg/kg (last two injections) in Dox equivalent) or PBS 
was i.v. injected on Day 3, 7, 11, 17, and 21. Tumor volume and body weight of mice were 
measured every other day. The tumor volume was calculated using the formula 
(length)×(width)
2
/2, where the long axis diameter was regarded as the length and the short axis 
diameter was regarded as the width. When the tumor volume reached 1500 mm
3
 (as 
predetermined endpoint) or the animal had become moribund or the body weight loss was 
beyond 20% of original weight, the animal was sacrificed. When an animal exited the study due 
to tumor volume or treatment related death, the final tumor volume recorded for the animal was 
used to calculate the mean tumor volume at subsequent time points. The time to endpoint (TTE) 
of each animal was defined as the day when its tumor volume had reached the predetermined 
endpoint. Animals classified as treatment-related deaths were assigned a TTE value equal to the 
day of death. Treatment efficacy was determined by tumor growth delay (TGD), which was 
defined as the increase in the median TTE in a treatment group compared to the control (PBS) 
group: TGD = TTE(T)－TTE(C) which was expressed in days, or as a percentage of the median 
TTE of the control group: %TGD = 100%×(TTE(T)－TTE(C))/TTE(C).13  
 
4.2.8 Long-term efficacy study of DCL-AAM+DBCO-VC-Dox against subcutaneous MDA-
MB-231 tumors. MDA-MB-231 tumors were established in 6 week-old female athymic nude 
mice by subcutaneous injection of MDA-MB-231 cells (1.5×10
6
 cells in HBSS/matrigel (50 μL, 
1/1, v/v)) into both flanks. When the tumors reached ~50 mm
3
, mice were randomly divided into 
4 groups (group 1: DCL-AAM+DBCO-VC-Dox; group 2: DBCO-VC-Dox; group 3: DCL-AAM; 
group 4: PBS; n = 5). DCL-AAM (60 mg/kg) was i.v. injected to group 1 and group 3 mice once 
daily for three consecutive days (Day 0, 1, and 2). DBCO-VC-Dox (12 mg/kg in Dox equivalent) 
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was i.v. injected on Day 3, 7, and 11. Tumor volume and body weight of each mouse were 
measured every four days. The endpoint of tumor volume was set at 1000 mm
3
. Data analyses 
were the same as the abovementioned long-term efficacy study against LS174T tumors. 
 
4.3 Results and Discussion 
After demonstrating the superior cancer-selective labeling capability of DCL-AAM and the 
resulting excellent targeting effect of DBCO-Cy5 via Click chemistry, I next aimed to develop 
the cancer-targeted therapy, ATTACK, using DCL-AAM and DBCO-doxorubicin conjugate 
(DBCO-VC-Dox) as specific substrates (Fig. 4.1a). DBCO-VC-Dox underwent rapid release of 
Dox in the presence of cathepsin B (Fig. 4.1b) and showed enhanced cellular uptake in DCL-
AAM treated LS174T cells in vitro (Fig. 4.1c). Covalently attached DBCO-VC-Dox by DCL-
AAM treated LS174T cells demonstrated its capacity to enter late endosomes/lysosomes, as 
exemplified by DBCO-Cy5 with low passive cell uptake (Fig. 4.2a). The highest Cy5 
fluorescence intensity clearly moved from the edges of the cells towards the center over the time 
of the uptake studies (Fig. 4.2b).  
 
In a short-term antitumor efficacy study, athymic nude mice bearing LS174T tumors were 
i.v. administered with DCL-AAM or PBS once daily for three days (Day 0, 1 and 2) and then i.v. 
administered with DBCO-VC-Dox on Day 3. At 48 h p.i. of DBCO-VC-Dox, quantification of 
retained drugs in tissues showed a 1.93-fold tumor accumulation of DBCO-VC-Dox in mice 
treated with DCL-AAM compared to control mice treated with PBS, while non-significant 
changes of DBCO-VC-Dox accumulation in liver, spleen, lung, heart, and kidney were observed 
(Fig. 4.3b). Tumors treated with DCL-AAM+DBCO-VC-Dox showed an apoptosis index of 52.8 
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± 5.5%, which was significantly greater than that of tumors treated with DBCO-VC-Dox only 
(23.6 ± 4.1%) (Fig. 4.3c-d). As negative controls, tumors treated with DCL-AAM or PBS 
showed much lower apoptosis index, 2.1 ± 0.8% or 2.6 ± 0.6%, respectively (Fig. 4.3c-d). These 
experiments confirmed that DCL-AAM mediated cancer-selective labeling could significantly 
improve the tumor accumulation and acute antitumor efficacy of DBCO-VC-Dox. 
 
To further understand how the enhanced tumor accumulation of DBCO-VC-Dox mediated 
by DCL-AAM labeling would impart improved antitumor activity, a separate efficacy study was 
conducted by monitoring the tumor volume over a prolonged period. Athymic nude mice bearing 
LS174T tumors were divided into 4 groups: DCL-AAM+DBCO-VC-Dox, DBCO-VC-Dox, 
DCL-AAM, and PBS. As compared to PBS and DCL-AAM groups, DCL-AAM+DBCO-VC-
Dox and DBCO-VC-Dox groups exerted greater tumor growth inhibition (Fig. 4.4a). Compared 
with DBCO-VC-Dox, DCL-AAM+DBCO-VC-Dox significantly reduced tumor growth rate 
from as early as Day 12. DCL-AAM+DBCO-VC-Dox improved the survival time of mice by 
231.4% compared to PBS group, which was substantially greater than that of DBCO-VC-Dox 
(45.9%) (Fig. 4.4b, Supplementary Fig. 4.1a). Together, DCL-AAM+DBCO-VC-Dox exerted 
greatly improved anticancer efficacy than DBCO-VC-Dox only, as a result of the enhanced 
tumor accumulation of drugs via Click chemistry.  
 
To extend the applicability of ATTACK to address unmet clinical needs, I evaluated the 
activity of DCL-AAM+DBCO-VC-Dox in additional preclinical models such as TNBC which is 
characterized by the limited expression of estrogen receptors, progesterone receptors, and 
HER2.
7, 14
 DCL-AAM was able to efficiently label MDA-MB-231 TNBC cells with azido 
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groups which improved the cellular uptake of DBCO-VC-Dox in vitro (Fig. 4.5a-c). In a long-
term efficacy study, athymic nude mice bearing MDA-MB-231 tumors were divided into 4 
groups: DCL-AAM+DBCO-VC-Dox, DBCO-VC-Dox, DCL-AAM, and PBS. DCL-AAM was 
i.v. administered on Day 0, 1, and 2. Subsequently, DBCO-VC-Dox was i.v. administered on 
Day 3, 7, and 11. Compared to PBS group, DCL-AAM group showed negligible difference in 
the tumor growth rate (Fig. 4.6a), excluding the influence of DCL-AAM alone on any observed 
antitumor effect. DCL-AAM+DBCO-VC-Dox and DBCO-VC-Dox increased the survival time 
of mice by 74.4% and 36.9%, respectively, compared to PBS group (Fig. 4.6b, Supplementary 
Fig. 4.2a). DCL-AAM+DBCO-VC-Dox exerted greater antitumor efficacy than DBCO-VC-Dox 
with a significantly smaller tumor volume from as early as Day 35 (Fig. 4.6a, Supplementary Fig. 
4.2b). These experiments demonstrated that DCL-AAM mediated labeling of MDA-MB-231 
tumors could improve the antitumor efficacy of DBCO-VC-Dox. 
 
4.4 Conclusion 
Cell-surface receptors provide the molecular recognition moieties for the design of cancer-
targeting technologies.
16
 Nearly all current targeting strategies rely on specific recognition of the 
endogenous protein receptors; one such technology that has received great success is the 
antibody/antigen technology. Antibody/antigen technology for cancer targeting, however, has 
several drawbacks such as large size of both receptor and targeting ligand, limited number of 
endogenous receptors, immunogenicity, high cost and difficulty of handling of antibody, and 
synthetic challenges of structure-specific drug-antibody conjugates for immunotherapy. In this 
study, I developed ATTACK (Scheme 4.1), an unprecedented in vivo targeting technology based 
on exogenous introduction of azido group, an artificial “antigen”, onto the surface of the target 
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cancer cells followed by highly efficient in vivo Click chemistry to target the introduced azido 
group. ATTACK is essentially the small molecule version of antibody/antigen targeting 
technology and has several obvious advantages such as much reduced size of receptor/targeting 
moieties, substantially increased cell-surface receptor numbers, ease of handling and synthesis of 
both azido-sugars and targeting substrates, low cost, and non-immunogenicity.
17-20
  
 
ATTACK therapy, using DCL-AAM as the cancer-selective azido-installing agent and 
DBCO-VC-Dox as the specific targeting therapeutics, exerted robust antitumor efficacy against 
MDA-MB-231 TNBC. DCL-AAM could efficiently label MDA-MB-231 TNBC of high 
HDAC/CTSL activity in vitro and in vivo with high efficiency, and thus resulted in enhanced 
antitumor efficacy of DBCO-VC-Dox. It is well known that there is a lack of efficient targeted 
therapies for the treatment of TNBCs due to the absence of characteristic cell-surface receptors
11
, 
however, DCL-AAM mediated labeling followed by targeting of DBCO-VC-Dox can 
circumvent this limitation because of its independence of endogenous receptor expressions. 
These experiments suggest that ATTACK is a promising targeting technology for diagnosis and 
treatment of TNBCs and very likely other cancers devoid of unique extracellular biomarkers.  
 
In conclusion, I developed ATTACK for in vitro and in vivo cancer-targeted labeling and 
therapy. High cancer-targeting efficiency and robust antitumor efficacies of ATTACK therapy 
using DCL-AAM and DBCO-VC-Dox as specific substrates were demonstrated in several tumor 
models, including primary LS174T colon cancer and MDA-MB-231 TNBC. Substantially 
reduced toxicity was also observed with the use of ATTACK therapy compared to free drug. The 
design of DCL-AAM can potentially be extended to various other types of diseases, as long as 
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endogenous disease-specific triggers can be identified and used to design the azido-sugar 
precursors. Further improved in vivo targeting efficiency can potentially be achieved through the 
use of drugs/agents with low passive accumulation in cancer cells, such as protein and nucleic 
acid based therapeutics. ATTACK has tremendous potential for eventual clinical applications to 
become a powerful small molecule based targeting technology.   
 
4.5 Figures and Schemes 
 
 
 
Scheme 4.1 Schematic illustration of ATTACK (active tissue targeting via anchored Click 
chemistry) technology: in vivo selective labeling of cancer cells with azido groups and 
subsequent cancer targeting via efficient Click chemistry. 
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Figure 4.1 (a) Structure of DBCO-VC-Dox with a cathepsin B-cleavable linker which consists 
of a dipeptide (val-cit), a self-immolative p-aminobenzylcarbamate, and a short polyethylene 
glycol segment (1k Da). Cleavage site of cathepsin B was shown by the red arrow. (b) Release 
profile of DBCO-VC-Dox in the presence of activated cathepsin B. (c) DBCO-VC-Dox uptake 
by LS174T cells with or without DCL-AAM pretreatment (72 h) over 30-min incubation. Cells 
without DBCO-VC-Dox treatment (0 min) were used as negative controls. Data were presented 
as mean ± SEM (n=6) and analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; 
***P ≤ 0.001). 
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Figure 4.2. Covalently attached DBCO-Cy5 entered endosomes/lysosomes in DCL-AAM 
treated LS174T cells. LS174T cells were pretreated with DCL-AAM (50 μM) for three days 
and labeled with DBCO-Cy5 (50 μM) for 1 h. After washing with PBS, cells were further 
incubated in fresh medium for different time (0, 3, 6, and 12 h), and imaged under a fluorescence 
microscope. (a) CLSM images of LS174T cells that were further incubated for 0, 3, 6, and 12 h, 
respectively. Endosomes/lysosomes were stained with Lysotracker green (green). Cell membrane 
and nuclei were stained with CellMask orange plasma membrane stain (orange) and Hoechst 
33342 (blue), respectively. Scale bar: 10 µm. (b) Cy5 fluorescence intensity profile over the 
longitudinal direction of cells from (a). For each cell, the Cy5 fluorescence intensity profile over 
the longitudinal direction was extracted from CLSM image using ZEN software, with the 
longitudinal diameter of cell normalized to 14.5 μm. The profiles were then averaged over 30 
cells for each group. 
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Figure 4.3 (a) Time frame of short-term efficacy study in athymic nude mice bearing LS174T 
tumors. DCL-AAM (60 mg/kg) was i.v. injected once daily for three days (Day 0, 1, and 2). 
Subsequently DBCO-VC-Dox (10 mg/kg in Dox equivalent) was i.v. injected on Day 3. Tumors 
were harvested for analysis at 48 h p.i. of DBCO-VC-Dox (on Day 5). (b) Retained drugs in 
tissues of drug-treated mice (n=3). (c) Representative TUNEL staining sections of LS174T 
tumors from mice treated with DCL-AAM+DBCO-VC-Dox, DBCO-VC-Dox, DCL-AAM, and 
PBS, respectively. Scale bar: 50 μm. (d) Quantification of TUNEL stains in (c) via ImageJ. The 
apoptosis index was determined as the ratio of apoptotic cell number (TUNEL, red) to the total 
cell number (DAPI, blue). Twenty tissue sections were counted per tumor (n=6). 
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Figure 4.4. DCL-AAM mediated tumor labeling significantly improved long-term 
antitumor efficacy of DBCO-VC-Dox against subcutaneous LS174T tumors in athymic 
nude mice. LS174T tumors were established in 6 week-old female athymic nude mice by 
subcutaneous injection of LS174T cells into both flanks. When the tumors reached ~50 mm
3
, 
mice were randomly divided into 4 groups (group 1: DCL-AAM+DBCO-VC-Dox; group 2: 
DBCO-VC-Dox; group 3: DCL-AAM; group 4: PBS; n = 5). DCL-AAM (60 mg/kg) was i.v. 
injected on Day 0, 1, 2, 15, and 16. DBCO-VC-Dox (12 mg/kg or 8 mg/kg in Dox equivalent) 
was i.v. injected on Day 3, 7, 11, 17, and 21. Tumor volume and body weight were measured 
every other day. (a) Average LS174T tumor volume of mice from different groups over the 
course of the efficacy study. Data were presented as mean ± SEM (n=10) and analyzed by one-
way ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). (b) Kaplan-Meier plots for 
all groups. Loss of mice was because of treatment-related death or euthanasia after the 
predetermined end point was reached.  
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Figure 4.5. DCL-AAM could efficiently label MDA-MB-231 and 4T1 cells and resulted in 
enhanced uptake of DBCO-VC-Dox in vitro. (a) CLSM images of MDA-MB-231 cells after 
incubation with DCL-AAM (50 μM), DCL-AAM (50 μM) + TSA (1 μM), and DCL-AAM (50 
μM) + Z-FY-CHO (50 μM), respectively, for 72 h and labeled with DBCO-Cy5 (50 μM) for 1 h. 
The cell nuclei and membrane were stained with DAPI (blue) and CellMask orange plasma 
membrane stain (green), respectively. Scale bar: 10 μm. (b) Average Cy5 fluorescence intensity 
of MDA-MB-231 cells following the same treatment in (a). DBCO-VC-Dox uptake by MDA-
MB-231 cells (c) and 4T1 cells (d) with or without DCL-AAM pretreatment (72 h) over different 
incubation time (30 min, 1 h, and 2 h). All the numerical data were presented as mean ± SEM 
(n=6) and analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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Figure 4.6 Long-term antitumor efficacy study in nude mice bearing subcutaneous MDA-MB-
231 tumors. DCL-AAM was i.v. injected on Day 0, 1, and 2. Subsequently DBCO-VC-Dox was 
i.v. injected on Day 3, 7, and 11. (a) Average MDA-MB-231 tumor volume of each group mice 
(n=10) over the course of the efficacy study. (b) Kaplan-Meier plots for all groups. Loss of mice 
was because of treatment-related death or euthanasia after the predetermined end point was 
reached. All the numerical data were presented as mean ± SEM and analyzed by one-way 
ANOVA (Fisher; 0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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Supplementary Figure 4.1. DCL-AAM mediated tumor labeling significantly improved 
long-term antitumor efficacy of DBCO-VC-Dox against subcutaneous LS174T tumors in 
athymic nude mice. (a) Survival analysis of mice from different groups. TTE: time to end point. 
TGD: tumor growth delay; TGD = TTE (treated group)－TTE (PBS group). %TGD = 100% × 
TGD/TTE (PBS group). (b) Statistical analyses of the tumor volumes by one-way ANOVA and 
Fisher’s LSD test (0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). (c) Body weight of mice from 
different groups over the course of the efficacy study. Curves were truncated when three or more 
mice were dead or sacrificed. 
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Supplementary Figure 4.2. DCL-AAM mediated tumor labeling significantly improved 
long-term antitumor efficacy of DBCO-VC-Dox against subcutaneous MDA-MB-231 
tumors in athymic nude mice. (a) Survival analysis of mice from different groups. TTE: time to 
end point. TGD: tumor growth delay; TGD = TTE (treated group)－TTE (PBS group). %TGD = 
100% × TGD/TTE (PBS group). (b) Statistical analyses of the tumor volume by one-way 
ANOVA and Fisher’s LSD test (0.01 < *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). (c) Body weight 
of mice from different groups over the course of the efficacy study. Curves were truncated when 
three or more mice were dead or sacrificed. 
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CHAPTER 5 
GLYCOPOLYESTER NANOPARTICLE FOR CANCER LABELING 
 
5.1 Introduction 
Chemotherapy provides vital cancer treatment but often suffers from undesired 
pharmacological profiles of anticancer agents, such as poor water solubility, fast renal clearance, 
large volume of distribution, and severe side effects.
1,2
 Drug loaded nanoparticle (NP) has 
emerged as a promising modality for cancer treatment.
3.4
 NP mediated cancer targeting has been 
attempted by modifying NP surface with targeting ligands (TLs) that can specifically bind to 
cancer-associated protein receptors.
5-7
 Although these NP-TLs have improved cellular uptake in 
the cancerous tissues, they often show very limited targeting in vivo and undesired immune 
response, the latter of which leads to fast clearance of NP-TLs from circulation and their elevated 
accumulation in liver and spleen.
8-12
 Alternative strategy to direct chemotherapeutic agents 
specifically to cancerous tissues with minimal effect on their distribution to other organs is 
clearly of great interest and importance for drug development and clinical oncology.   
 
Click chemistry has been widely used in bioconjugation, cell labeling, and protein profiling 
because of their favorable features such as small ligand size, biocompatibility, high reaction rate, 
and excellent specificity and selectivity.
13,14
 The discovery that unnatural sugars (e.g., 
Ac4ManAz) can metabolically label cancer cell surface with azido groups has enabled the 
application of Click chemistry to cancer targeting.
15-17
 Differing from the targeting of the protein 
receptors by existing TLs which is mediated by hydrophobic/electrostatic interactions, the 
targeting of metabolically expressed azido-sugar is mediated by the formation of covalent bonds 
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through efficient Click chemistry. Apart from the above-mentioned features of Click reaction, 
this sugar/Click chemistry mediated targeting strategy also avoids immune response and benefits 
from the much larger number density of cell surface sugars compared to proteins.
15-18
 However, 
the metabolic labeling process of azido-sugar also occurs in healthy cells.
17
 To develop the two-
step strategy (metabolic labeling followed by Click chemistry) viable for cancer targeting, the 
key challenge is to specifically deliver the azido-sugar to the cancer area. 
  
In this study, I developed a new targeting strategy by integrating NP-mediated passive 
targeting via the Enhanced Permeability and Retention (EPR) effect
19-21
 and azido-sugar 
mediated cancer cell labeling. I avoided the use of azido-sugar encapsulated NPs, as premature 
sugar release and uncontrolled release kinetics may make it difficult to achieve selective cancer 
labeling.
22
 An azido-sugar conjugated NP with great loading stability and controlled sugar 
release profiles can potentially enable highly efficient cancer cell labeling, which facilitates the 
subsequent Click chemistry mediated in vivo cancer targeting. Specifically, I designed azido-
sugar conjugated glycopolyester NP (GP-NP) via azido-sugar initiated ring-opening 
polymerization (ROP) of 5-(4-(prop-2-en-1-yloxy)benzyl)-1,3-dioxolane-2,4-dione (allyl (all)-
OCA) followed by nanoprecipitation of the resulting GP(all) with PEG-P(all) (Scheme 5.1a). 
GP-NP showed excellent stability under physiological conditions while underwent controlled 
release of azido-sugars in the presence of cellular esterase for metabolic cell labeling (Scheme 
5.1b). GP-NP mediated tumor labeling significantly improved tumor accumulation and retention 
of dibenzocyclooctyne (DBCO)-Cy5 and DBCO-doxorubicin conjugate. 
 
5.2 Materials and Methods 
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5.2.1 General procedures for ring-opening polymerization of allyl-OCA. R-OH (1 molar 
equivalent) and 4-dimethylaminopyridine (1 molar equivalent) were dissolved in anhydrous 
DCM in a glove box, followed by the addition of allyl-OCA (20, 50, or 100 molar equivalents) in 
DCM in one portion. The reaction mixture was stirred at room temperature for 16 h. One drop of 
reaction solution was taken out for FTIR analysis to confirm the complete consumption of allyl-
OCA (disappearance of the peak at around 1810 cm
-1
). The mixture was then precipitated into 
diethyl ether. Collected precipitates were washed with anhydrous diethyl ether and dried for use. 
 
5.2.2 Preparation of GP-NP and PP-NP. GP(all)20 or PP(all)20 (5 mg) and mPEG5k-P(all)20 (5 
mg) were dissolved and well mixed in anhydrous DMF (1 mL). The mixture was then dropwise 
added to vigorously stirred nanopure water (20 mL). A turbid solution was obtained immediately. 
After addition of polymer solution, the mixture was stirred for another 2 h, and then transferred 
into a dialysis tube. The NPs were dialyzed against deionized water for 48 h, concentrated via 
ultracentrifugation, and stored for use. 
 
5.2.3 In vitro cell labeling experiment. LS174T cells were seeded onto coverslips in a 6-well 
plate with a cell density of 40 k/well. GP-NP (25 μM in GP equivalent) or PP-NP (25 μM in PP 
equivalent) was added and the cells were incubated at 37
o
C for 72 h. The medium was removed 
and washed with PBS for three times. DBCO-Cy5 (25 μM) in Opti-MEM was added and the 
cells were incubated for another 1 h. Cells were then washed, fixed, and stained with DAPI. The 
coverslips were mounted on microscope slides with the addition of ProLong Gold antifade 
reagent and the prepared samples were stored in dark for imaging. 
 
 - 80 - 
5.2.4 Flow cytometry analysis. LS174T cells were seeded onto coverslips in a 6-well plate at a 
cell density of 40 k/well. GP-NP (25 μM in GP equivalent), PP-NP (25 μM in PP equivalent) or 
PBS was added and incubated with cells for 72 h. After removal of the medium and multiple 
washing steps, DBCO-Cy5 (25 μM) in opti-MEM was added and incubated with cells at 37oC 
for 1 h. Cells were then washed, lifted by trypsin solution, and transferred to test tubes with the 
addition of 4% PFA solution. Ten thousand cells per sample were analyzed by flow cytometry 
and data analysis was performed on FCS Express software. 
 
5.2.5 In vivo and ex vivo fluorescence imaging. LS174T tumor models were established on 6 
week-old female 01B74 athymic nude mice by subcutaneous injection of LS174T colon cancer 
cells (1.5 million) into both flanks. When the tumors grew to a diameter of ~ 6 mm, GP-NP (40 
mg/kg in sugar equivalent) or PP-NP (same amount of NPs) or PBS was i.v. administered once 
daily for three days. 24 h after the last injection, DBCO-Cy5 (6 mg/kg) was i.v. injected. Nude 
mice were placed on the sample stage equipped with anesthesia input and output ports, and 
imaged by the Bruker Xtreme In-Vivo Fluorescence Imaging System at selected time points. The 
excitation filter was set at 630 nm and emission filter was set at 700 nm. Collected images were 
analyzed by the Bruker molecular imaging software. Major organs and tumors were dissected 
from mice at 6, 24 or 48 h post injection of DBCO-Cy5, and imaged ex vivo. Ex vivo images 
were quantified by measuring fluorescence intensity at selected ROIs. All values were expressed 
as means ± standard deviation (n=3). After ex vivo imaging, tumors were immediately frozen in 
O.C.T. compound, sectioned, and stained with DAPI. Coverslips were mounted on the 
microscope slides with the addition of ProLong Gold antifade reagent and the prepared samples 
were stored in dark for confocal imaging. 
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5.2.6 Synthesis of DBCO-hz-Dox. DBCO-NHS (0.1 mmol) was dissolved in anhydrous 
acetonitrile (1 mL), followed by addition of hydrazine (0.5 mmol). The mixture was stirred at 
room temperature for 30 h. The solvent was removed under reduced pressure and the residue was 
dissolved in anhydrous DMF (500 μL). Doxorubicin hydrochloride (0.1 mmol) in DMF (500 μL) 
was added, followed by addition of one drop of concentrated hydrochloric acid. The reaction 
mixture was stirred at 40
o
C for 48 h. DBCO-hz-Dox was obtained via precipitation of the 
reaction mixture into diethyl ether and washed with diethyl ether for twice (overall yield: 70%). 
LRMS (ESI) m/z: exact mass calculated for C46H45N4O12 [M+H]
+
 845.3, found 845.6. 
 
5.2.7 Release Kinetics of DBCO-hz-Dox. DBCO-hz-Dox (1 mg) was dissolved in 1 mL of PBS 
with a pH value of 5.0 or 7.4, and incubated at 37
o
C with gentle shaking. At selected time points 
(0.25, 0.5, 1, 2, 4, 6 h), 10 μL of DBCO-hz-Dox solution was injected into HPLC. Percentage of 
released Dox was determined by the standard curve of Dox. 
 
5.2.8 Antitumor Efficacy study. LS174T tumor models were established on 6 week-old female 
01B74 athymic nude mice by subcutaneous injection of LS174T colon cancer cells (1.5 million) 
into both flanks. When the tumors grew to a size of ~ 6 mm, mice were randomly divided into 
five groups (group 1: GP-NP/DBCO-hz-Dox; group 2: PP-NP/DBCO-hz-Dox; group 3: DBCO-
hz-Dox; group 4: GP-NP; group 5: PBS; n = 3). GP-NP (40 mg/kg in sugar equivalent) or PP-NP 
(same amount of NPs) was i.v. injected once daily for three days (Day 1-3), and DBCO-hz-Dox 
(10 mg/kg Dox equivalent) was i.v. injected on Day 4. At 48 h p.i. of DBCO-hz-Dox, major 
organs and tumors were harvested. Tumors were cut into halves. Organs and half of the tumors 
were homogenized and lysed in lysis buffer. Retained Dox was quantified via HPLC method. 
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The other half of tumors were frozen with O.C.T. compound, and sectioned on cryostat with a 
thickness of 6 μm. Cell apoptosis in tumors was analyzed via TUNEL assay using in situ cell 
death detection kit. TUNEL staining was performed following the manufacture’s manual. The 
tumor sections were imaged with the confocal laser scanning microscopy at 20× magnification.  
 
5.3 Results and Discussion 
Hydroxyl-containing-substrate initiated ROP of O-carboxyanhydrides (OCAs) provides an 
efficient method to prepare biodegradable polyesters with controlled molecular weights (MWs), 
various functionalities, and tunable physicochemical properties.
23
 Such substrate-polyester 
conjugates can be used to make polyester NPs to control the release of the substrate.
24,25
 As the 
exposure of the 1-OH of Ac4ManAz is essential for its metabolic activity,
15,16 
I envisioned that 
using this 1–OH group to initiate ROP of OCAs to yield sugar-conjugated polyesters can not 
only achieve controlled sugar release profiles but also “preserve” cell labeling capability until the 
azido-sugar is released from the polymeric structure. Ac3ManAzOH was obtained via site-
specific deprotection of Ac4ManAz (Scheme 5.1a). GP(all)s with well controlled MWs and 
narrow polydispersities were prepared via Ac3ManAzOH initiated ROP of all-OCA using 4-
dimethylaminopyridine (DMAP) as the catalyst. I selected GP(all)20, a 20-mer GP, throughout 
this study due to its highest sugar contents among all GP(all)s synthesized. Pyrene-P(all)20 (PP) 
and PEG5k-P(all)20 (PEG-P(all)) were similarly prepared using 1-pyrenebutanol and methoxy 
polyethylene glycol (mPEG, MW = 5k Da) as the initiator, respectively. 
 
I then prepared NPs via nanoprecipitation of GP (or PP) with PEG-P(all). The resulting GP-
NP had an average diameter of 143 nm and a narrow PDI of 0.07, as determined by dynamic 
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light scattering (DLS, Fig. 5.1a). TEM showed a smaller diameter, at around 113 nm (Inset, Fig. 
5.1a). PP-NP with a similar diameter was confirmed by DLS and TEM analysis. Both GP- and 
PP-NP showed remarkable stability in 50% human serum, evidenced by the negligible size 
changes over 9 days. To understand the sugar release kinetics of GP-NP, I conjugated DBCO-
Cy5 to GP first to yield Cy5-labeled GP (Cy5 GP) and then prepared Cy5-labeled GP-NP (Cy5 
GP-NP) via nanoprecipitation of Cy5 GP with PEG-P(all). ~50% of sugar moieties were released 
from GP-NP in 24 h in the presence of esterase (Fig. 5.1b), showing a controlled release rate on 
the same order of magnitude as the rate of metabolic labeling process of unnatural sugars.
26
 
CLSM images of LS174T cells incubated with Cy5 GP-NP for 2 h  showed the overlay of Cy5 
signal with LysoTracker Green signal, which confirmed that GP-NP entered late endosomes and 
might release sugar moities there for subsequent cell labeling. 
 
I next evaluated GP-NP with covalent attachment of azido-sugar for cell labeling. LS174T 
cells were incubated with GP-NP or PP-NP for 72 h and further incubated with DBCO-Cy5 for 1 
h. Confocal images of LS174T cells treated with GP-NP showed clear and uniform Cy5 
fluorescence on the cell surface (Fig. 5.1c, upper panel) in comparison to the negligible Cy5 
fluorescence observed in cells treated with PP-NP (Fig. 5.1c, lower panel), indicating the 
successful labeling of LS174T cells with azido groups by GP-NP. Flow cytometry analysis also 
showed the significantly enhanced Cy5 fluorescence intensity of LS174T cells treated with GP-
NP than cells treated with PP-NP. To confirm that the azido groups were expressed in the form 
of glycoproteins, western blot analysis of LS174T cells with GP-NP or PP-NP treatment was 
conducted. By incubating with biotin-PEG4-phosphine, azido-modified glycoproteins were 
converted to biotinylated ones and thus could be easily detected. LS174T cells treated with GP-
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NP showed a series of protein bands, while cells treated with PP-NP only showed two 
endogenous biotinylated protein bands (Fig. 5.1d). These results substantiated the successful 
metabolic incorporation of azido groups into cell-surface glycoproteins. 
 
After demonstrating in vitro labeling property of GP-NP, I next investigated its cancer 
labeling capability in vivo and the resulting Click reaction mediated targeting effect. GP-NP (or 
PP-NP) was i.v. administered to athymic nude mice bearing subcutaneous LS174T tumors once 
daily for three days. At 24 h p.i., DBCO-Cy5 was i.v. injected and its biodistribution was 
monitored via in vivo fluorescence imaging (Fig. 5.2a). At 6 h and 24 h p.i., a clear fluorescence 
contrast between tumors and the rest of the body was observed in mice pretreated with GP-NP, 
while tumors in PP-NP group showed similar Cy5 retention to the rest of the body, indicating the 
enhanced tumor retention of DBCO-Cy5 by Click reaction in mice pretreated with GP-NP (Fig. 
5.2b). Ex vivo imaging of tumors in GP-NP group showed a 2.05-fold Cy5 FI of the PP-NP 
group at 24 h p.i. of DBCO-Cy5 (Fig. 5.2c-d). Confocal images of tumor sections from GP-NP 
group also showed much stronger Cy5 FI than PP-NP group (Fig. 5.2e). 
 
To understand the enhanced tumor retention of DBCO-Cy5 resulted from Click reaction, I 
analyzed the biodistribution of DBCO-Cy5 over time in mice pretreated with GP-NP and PP-NP, 
respectively. At selected time points (6 h, 24 h, and 48 h p.i. of DBCO-Cy5), tumors and major 
organs were harvested for ex vivo imaging (Fig. 5.3a). GP-NP group showed much better tumor 
retention of DBCO-Cy5 over time compared to PP-NP group, with the Cy5 retention ratio in 
tumor increased from 1.68 at 6 h p.i. to 2.05 at 24 h p.i. to 2.91 at 48 h p.i.. (Fig. 5.3b, black line). 
The increasing tumor retention ratio over time suggests that DBCO-Cy5 was well retained by the 
 - 85 - 
expressed azido groups in the tumor area of GP-NP pretreated mice. Much smaller Cy5 retention 
ratio of GP-NP group to PP-NP group in the healthy organs including liver, spleen, lung, heart, 
and kidney was observed at 48 h p.i. (Fig. 5.3b). The dramatically increased tumor-to-liver and 
tumor-to kidney ratios of Cy5 FI at 24 h and 48 h p.i. also testified the excellent tumor retention 
of Cy5 in GP-NP group than in PP-NP group (Fig. 5.3c-d). For other organs including spleen, 
heart, lung, and kidney, GP-NP pretreated mice also showed much higher tumor-to-organ ratio 
than the control mice pretreated with PP-NP at any selected time point. These data demonstrated 
that the GP-NP pretreatment resulted in the dramatic tumor targeting/retention of DBCO-Cy5. 
 
After demonstrating that GP-NP pretreatment could significantly enhance the tumor 
retention of DBCO-Cy5 via Click reaction, I next investigated whether GP-NP pretreatment 
would lead to the enhanced anticancer efficacy of small molecule DBCO-drug conjugates. 
DBCO-hz-Dox with a pH-responsive hydrazone linker was first synthesized (Fig. 5.4a). DBCO-
hz-Dox showed good stability at pH 7.4, while released Dox rapidly at pH 5.0 (Fig. 5.4b), 
suggesting that Dox may be subject to faster release in acidic cellular organelles, such as 
endosome. In vitro anticancer efficacy of DBCO-hz-Dox against LS174T cells was studied via 
MTT assay, which showed an IC50 value of 0.54 μM (Fig. 5.4c). In an acute antitumor efficacy 
study, athymic nude mice bearing LS174T tumors were pretreated with GP-NP or PP-NP once 
daily for three days, and i.v. injected with DBCO-hz-Dox. At 48 h p.i., tumors were harvested 
and analyzed for drug retention and cell apoptosis via TUNEL assay. GP-NP pretreatment 
improved the tumor accumulation of DBCO-hz-Dox by 50% and resulted in a much higher 
apoptosis index (57.4 ± 5.1%) than PP-NP pretreatment (31.8 ± 3.2%), presumably due to the 
enhanced tumor retention of DBCO-hz-Dox by the expressed azido groups in GP-NP group (Fig. 
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5.4e). Tumors treated with DBCO-hz-Dox alone showed comparable apoptosis (27.7 ± 2.8%) to 
tumors treated with PP-NP+DBCO-hz-Dox (31.8 ± 3.2%), which further testified the importance 
of azido-sugars in tumor labeling. As negative controls, tumors treated with GP-NP or PBS 
showed much lower apoptosis index, with an apoptosis index of 6.3 ± 1.0% and 4.5 ± 0.9%, 
respectively. 
 
5.4 Conclusion 
In this study, I developed an azido-sugar conjugated GP-NP for tumor labeling and targeted 
delivery of DBCO-therapeutic agents. I demonstrated that GP-NP mediated labeling of tumor 
cells with azido groups could significantly improve the retention of DBCO-Cy5 and DBCO-drug 
conjugate, with a much slower tumor clearance rate over time. More remarkably, GP-
NP+DBCO-drug mediated targeting has limited effect on the distribution and retention of drugs 
in other non-cancerous organs. Together, reduced dose and side effects are anticipated via the 
use of this two-step targeted chemotherapy. Direct conjugation of targeting ligand to drug-
containing NP has been demonstrated to be very unreliable and inefficient for in vivo targeting.
8-
10
 This reported GP-NP, with a typical size and surface PEG-coating, coupled with DBCO-drug, 
may represent by far one of the most efficient in vivo uses of NP for targeting applications, is 
highly clinical applicable, and is potentially cancer type-independent. 
 
5.5 Figures and Schemes 
 
 - 87 - 
 
Scheme 5.1. Schematic representation of the synthesis and metabolic labeling process of GP-NP. 
(a) Synthesis of glycopolyester (GP(all)) via Ac3ManAzOH initiated ROP of all-OCA, and 
preparation of GP-NP via nanoprecipitation method. (b) GP-NP mediated labeling of cancer cells 
with azido groups and subsequent targeting by DBCO-cargo via copper-free Click chemistry. 
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Figure 5.1. (a) DLS analysis of GP-NP prepared from nanoprecipitation of GP and PEG-P(all). 
Inset: TEM characterization of GP-NP. (b) Release profile of sugar moieties from GP-NP in 
presence of esterase. Data were presented as average ± standard deviation, n = 3. (c) CLSM 
images of LS174T colon cancer cells after incubated with GP-NP and PP-NP, respectively for 72 
h and subsequently labeled with DBCO-Cy5 for 1 h. The cell nucleus was stained with DAPI. 
Scale bar: 10 μm. (d) Western blot analysis of LS174T cells after treated with GP-NP and PP-NP, 
respectively for 72 h. 
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Figure. 5.2. In vivo labeling study of GP-NP and PP-NP. (a) Time frame of in vivo labeling 
study. Athymic nude mice bearing LS174T tumors on both flanks were i.v. injected with GP-NP 
(40 mg/kg in sugar equivalent) or PP-NP (same amount of NP) once daily for three days, and 
subsequently detected by DBCO-Cy5 (6 mg/kg). (b) In vivo whole body fluorescence imaging of 
mice pretreated with GP-NP (upper row) or PP-NP (lower row) at 1 h, 6 h, and 24 h p.i. of 
DBCO-Cy5, respectively. Tumors were shown by yellow arrows. Excitation wavelength was set 
at 630 nm, and emission wavelength was set at 700 nm. (c) Ex vivo fluorescence imaging of 
tumors and major organs (1-liver, 2-spleen, 3-lung, 4-heart, 5-kidney, 6-kidney, 7, 8-tumors). (d) 
Quantification of Cy5 FI of tumors and major organs from ex vivo images. Data were presented 
as average ± standard deviation, n = 3. Statistical significance analysis was performed by Two-
Sample Unpaired Student’s t-test; 0.05 < p, 0.01 < *p ≤ 0.05 and **p ≤ 0.01 were considered 
statistically non-significant, significant, and highly significant, respectively. (e) CLSM images of 
tumor sections from mice treated with GP-NP/DBCO-Cy5, PP-NP/DBCO-Cy5, and PBS, 
respectively. Cell nucleus was stained with DAPI (blue). Scale bar: 20 μm. The parameters for 
confocal imaging were kept the same for all samples.  
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Figure 5.3. GP-NP mediated enhanced tumor retention of DBCO-Cy5. (a) Time axis of in vivo 
labeling study. Athymic nude mice bearing LS174T tumors on both flanks were i.v. injected with 
GP-NP (40 mg/kg in sugar equivalent) or PP-NP (same amount of NP) once daily for three days, 
and subsequently detected by DBCO-Cy5 (6 mg/kg). (b) Cy5 retention ratio of GP-NP treated 
mice to PP-NP treated mice in tumor and major organs at 6 h, 24 h, and 48 h p.i., respectively. 
Cy5 retention ratio of (c) tumor to liver and (d) tumor to kidney over time (6 h, 24 h, and 48 h 
p.i.) in mice treated with GP-NP (black line) and PP-NP (red line), respectively. Data were 
presented as average ± standard deviation, n = 3.  
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Figure 5.4. (a) Structure of pH-responsive DBCO-hz-Dox. (b) Release kinetic profiles of 
DBCO-hz-Dox at pH 5.0 and 7.4, respectively. (c) In vitro cytotoxicity of DBCO-hz-Dox and 
free Dox against LS174T colon cancer cells, as determined by MTT assay. (d) Representative 
TUNEL staining sections of harvested LS174T tumors after different treatments. Scale bar: 50 
μm. (e) Quantification of TUNEL stains via ImageJ. 20 tissue sections were counted per tumor, 
n=6. 
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CHAPTER 6 
TARGETED ULTRASOUND ASSISTED CANCER-SELECTIVE LABELING 
AND IMAGING 
 
 
6.1 Introduction 
As an efficient method of incorporating chemical groups into cell surface glycoproteins, 
metabolic labeling of unnatural sugars has been widely used for glycan visualization, 
glycoproteomics, and cell labeling.
1-3
 Recently, researchers have shown increasing interest in 
applying it to cancer targeting by coupling with bioorthogonal chemistries.
4-6
 In the first step, 
unnatural sugars with azides are delivered and metabolized in the cancerous tissues, followed by 
the targeted delivery of DBCO-bearing therapeutics via Click chemistry in the second step. 
Despite being a two-step process, this combinational strategy has several advantages in cancer 
targeting: 1) excellent targeting can be achieved by taking advantage of the rapid, highly 
efficient Click chemistry; 2) receptor saturation and immunogenicity problems in conventional 
protein-based targeting strategies can be avoided by using manually installed chemical 
receptors;
7-9
 and 3) small-molecule DBCO as targeting ligands can be easily incorporated into 
therapeutic agents with tunable density. One key challenge in using this two-step strategy for in 
vivo cancer targeting is to specifically deliver the azido-sugars to the cancerous tissues. Kim et 
al.
6
 used chitosan nanoparticles to deliver azido-sugars to cancers by taking advantage of the 
EPR effect of nanoparticles, but the targeting efficiency was very low with limited selectivity.  
 
Ultrasound (US) imaging is widely used and recognized as a safe medical tool for disease 
diagnosis and treatment.
10-13
 microbubbles (MBs) that entrap gas in a biocompatible material to 
form micron-sized particles have achieved great success as US contrast agents (UCAs) due to 
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their high US reflectivity and great stability.
14
 It is well established that high US pressures cause 
expansion and contraction of MBs, resulting in their disruption.
15-17
 A secondary effect of MB 
destruction is the temporary increase of capillary permeability and production of transient 
poration in cell membranes.
18-21
 I envisioned that cancer-localized US with accurate tissue 
targeting capability could potentially be used to induce the release of azido-sugars from MBs 
specifically in the cancerous tissues,
22-24
 and designed Ac4ManAz-loaded MBs (Ac4-MBs) for 
effective in vivo cancer-selective labeling (Scheme 6.1). In the presence of high US pressures 
localized in the cancerous tissues, the MBs collapsed and released azido-sugar loaded liposomes, 
and meanwhile the temporarily increased capillary and cellular permeability facilitated the tumor 
penetration and cellular uptake of the released liposomes. The released Ac4ManAz then 
metabolically labeled the tumor cells with azido groups which mediated targeted retention of 
DBCO-cargo for cancer imaging and potential cancer treatment. 
 
6.2 Materials and Methods 
6.2.1 Preparation of Ac4ManAz-loaded liposomes functionalized with activated carboxylates. 
Hydrogenated L-α-phosphatidylcholine (HSPC, 5 mg), cholesterol (1.7 mg) and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[succinimidyl (polyethylene glycol)-2000] (DSPE-PEG2k-
NHS, 3.5 mg) were dissolved in anhydrous chloroform (300 μL), followed by the addition of 
Ac4ManAz (2 mg) in chloroform (100 μL). The mixture was left to dry for 12 h to form a lipid 
film. A hydration buffer (100 mM ammonium sulfate buffer, 300 μL) was added and the mixture 
was vortexed for 1 min. After incubating in a 60
o
C water bath for 15 min, the lipid mixture was 
further incubated at 30
o
C for 2 h. The lipid mixture then underwent five freeze-thaw cycles using 
liquid nitrogen and a 60
o
C water bath, and was further incubated at 37
o
C for at least 6 h. The 
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liposomal suspension was then fine sized by extruding successively through a mini extruder 
equipped with a membrane filter (100 nm pore size) and two syringes for at least 15 times. 
Ac4ManAz-loaded liposomes were then purified by passing through a Sephadex G100 column 
using ammonium sulfate buffer (150 mM) as the eluent. Collected liposomal solution was 
characterized by DLS and stored at 4
o
C for use. For the preparation of blank liposomes, the 
procedures were the same except for not adding the Ac4ManAz solution during the lipid film 
formation step.  
 
6.2.2 Preparation of amine-functionalized MBs. 4 mL of 5% BSA (w/v) and 12 mL of 15% 
dextrose (w/v) were mixed in a 50 mL centrifuge tube, infused with perfluorobutane gas to 
saturate the mixture, and sonicated for 70 seconds using a 20 kHz Fisher 500 sonic dismembrator 
with a 1.9 cm diameter sonic horn to form MBs. Capped syringes containing MB solution were 
stored plunger-up in racks at 4
o
C. Larger MBs rose to the plunger within 6 h to form a distinctly 
white band. The lower milky fraction containing 1 μm-diameter MBs was collected. Size and 
size distribution of MBs was characterized by DLS. The MB solution was stored at 4
o
C. 
 
6.2.3 Preparation of Ac4ManAz-loaded MB (Ac4-MB) and blank MB. Ac4ManAz-loaded 
liposomes or blank liposomes functionalized with activated carboxylates (20 mg/mL, 0.5 mL) in 
ammonium sulfate buffer and amine-functionalized MBs (3.6×108/mL, 2 mL) in PBS were 
mixed in a syringe, and shaken gently on a rotary plate for 24 h. The syringe was placed plunger-
up in a rack and stored at 4
o
C overnight. The milky fraction containing MBs on the top was 
collected into another syringe. To purify the prepared Ac4-MB or blank MB, fresh PBS was 
added to dilute the MB solution and the syringe was stored plunger-up in a rack at 4
o
C overnight. 
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The milky fraction containing MBs on the top was collected. The purification steps were 
repeated once to completely remove unconjugated liposomes. To determine the sugar loading, 
Ac4-MB was disrupted under US exposure and treated with Triton X100, followed by HPLC 
measurements. 
 
6.2.4 Stability of Ac4-MB and blank MB in 10% FBS. Ac4-MB was dispersed in 10% FBS (3 
mL), and incubated at 37
o
C. The diameter and number density of Ac4-MB were monitored via 
DLS at selected time points. 
 
6.2.5 Double passive cavitation detection (DPCD) characterization of Ac4-MB and blank MB. 
The double passive cavitation detection (DPCD) experiments involved a transmit 4.6-MHz 
transducer and two receive 13.8- and 14.6-MHz transducers. Three-cycle tone bursts with a pulse 
repetition frequency of 10 Hz at the transmit center frequency were generated using a pulse-
receive system (RAM-5000, RITEC Inc., Warwick, RI). Several thousand signals (8 series of 
500 signals for each tested incident peak rarefactional pressure amplitude (PRPA)) were acquired. 
The complete setup including the transmit PRPA calibration procedures has been fully described 
elsewhere.
2,3
 The DPCD analysis of collapsed ultrasound contrast agents (UCAs) (MBs) 
involved categorizing the UCAs according to a classification scheme based on the presence or 
absence of postexcitation signals (PESs). PES is defined as a secondary, short, broadband 
response typically occurring between 1 and 5 μs after the principle response. In this study, the 
measurement (MB collapse) criteria were based on the 5% and 50% postexcitation thresholds. 
These collapse criteria are defined as the level at which a certain percentage of the total 
population of MBs transiently collapsed with PES for an applied PRPA. It is determined as the 
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ratio between the total number of signals exhibiting PES and the total number of signals 
associated with the presence of a single bubble in the confocal region. Postexcitation curves were 
then obtained using a modified logistic regression using Matlab (The MathWorks Inc., Natick, 
MA) to fit the experimental data, allowing the evaluation of the 5% and the 50% postexcitation 
thresholds and their 95% confidence intervals.
2,3
 
 
6.2.6 In vitro cell labeling experiment. 4T1 cells were seeded onto coverslips in a 6-well plate 
with a cell density of 40 k per well and allowed to attach for 12 h. Ac4-MB (50 μM in sugar 
equivalent) or blank MB (same amount of MB) was then added. Cells incubated with Ac4-MB 
were treated with focused US: the 6-well cell plate was placed upside down to allow the MBs to 
rise to the bottom surface of the cell plate where the cells were attached and the US was focused. 
After treatment with US for 1 min, the cells were incubated at 37
o
C for 72 h. The medium was 
removed and washed with PBS for three times. DBCO-Cy5 (25 μM) in Opti-MEM was added 
and the cells were incubated for another 1 h. Cells were then washed, fixed with 4% PFA 
solution, and stained with DAPI for 10 min. The coverslips were mounted on microscope slides 
and the prepared samples were stored in the dark for imaging. 
 
6.2.7 In vivo labeling experiment with intratumoral injection of Ac4-MB or blank MB: (1) 
Western blot analysis of tumor tissues: 4T1 tumor models were established in 6-week-old female 
BALB/c mice by subcutaneous injection of 4T1 cells (1.5 million in matrigel/HBSS, 1/1, v/v) 
into both flanks. When the tumors reached to a diameter of approximately 5 mm, the hair over 
the tumor area was shaved, depilated and a layer of gel (to maximize US transmission through 
the skin surface) was spread over the tumors prior to US imaging. Ac4-MB (25 mg/kg in sugar 
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equivalent) or blank MB (same amount of MB) was injected into the tumors of Balb/c mice in 1 
min, with simultaneous treatment of targeted US. The right tumors were treated with high-
amplitude US pressure pulses (the US system’s output was set to a maximum at 100% to 
collapse MBs), while the left tumors were treated with low-amplitude US pressure pulses (the 
US system’s output was set to a very low amplitude of 4% so that the MBs would not collapse 
and yet still provide US imaging capability). US was continuously applied for another 1 min 
after the removal of the syringe. After three days, mice were euthanized and tumors were 
harvested and homogenized in lysis buffer (1% SDS, 100 mM Tris
.
HCl, pH 7.4) containing 1 
tablet protease inhibitor (EDTA-free). The lysates were incubated at 4
o
C for 30 min, followed by 
centrifugation at 3000 rcf for 10 min to remove insoluble cell debris. The total soluble protein 
concentration was determined by bicinchoninic acid (BCA) assay and adjusted to 5 mg/mL. 
Then 20 μL of the lysate was blocked with 5% bovine serum albumin (BSA) for 2 h and further 
incubated with DBCO-Cy3 in 5% BSA (20 μM) for 1 h. A loading buffer was added to each 
sample and samples were loaded onto a 10% SDS-PAGE gel after heating at 95
o
C for 5 min. 
After running the gel at 120 V for 120 min, proteins were transferred to a Hybond P membrane. 
The protein bands were visualized using an Image Quant LAS 4010 system with a Cy3/Cy3 
(excitation/emission) channel. (2) In vivo and ex vivo biodistribution of DBCO-Cy5: In a 
separate study, three days after the intratumoral injection of Ac4-MB or blank MB and US 
treatment, DBCO-Cy5 (5.0 mg/kg) was intravenously (i.v.) injected. BALB/c mice were placed 
on the sample stage equipped with anesthesia input and output ports, and imaged by the Bruker 
Xtreme In-Vivo Fluorescence Imaging System at 1 h, 5 h, 24 h, and 48 h post injection (p.i.) of 
DBCO-Cy5, respectively. The excitation filter was set at 630 nm and the emission filter was set 
at 700 nm. Collected images were analyzed by the Bruker molecular imaging software. Tumors, 
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liver, lung, kidneys, heart, spleen, and brain were harvested at 48 h p.i. of DBCO-Cy5 and 
imaged ex vivo using the Bruker Xtreme In-Vivo Imaging System. Ex vivo images were 
quantified by measuring FI at selected region of interest (ROI). All values were expressed as 
means ± standard deviation (n = 3).  
 
6.2.8 In vivo labeling experiment with i.v. injection of Ac4-MB and blank MB: 4T1 tumors 
were established in 6-week-old female BALB/c mice by subcutaneous injection of 4T1 cells (1.5 
million in matrigel/HBSS, 1/1, v/v) into both flanks. When the tumors reached a diameter of 
approximately 5 mm, the mice were divided into 4 groups: Ac4-MB with US treatment on the 
left tumors (Group 1), blank MB with US treatment on the left tumors (Group 2), Ac4-MB 
without US treatment (Group 3), and PBS without US treatment (Group 4). Prior to US imaging, 
the hair over the tumor area was shaved and a layer of gel (to maximize US transmission through 
the skin surface) was spread over the tumor. Ac4-MB (50 mg/kg in sugar equivalent, Group 1) or 
blank MB (same amount of MB, Group 2) was i.v. injected via the tail vein in 1 min, with 
simultaneous treatment of targeted US on the left tumors. The US was continuously applied for 
another 1 min after the removal of the syringe. The right tumors without US treatment were used 
as a control. A total of three Ac4-MB injections were given at an interval of 24 h. Group 3 and 
group 4 mice were i.v. administered with Ac4-MB (50 mg/kg in sugar equivalent) and PBS, 
respectively once daily for three days without any US treatment. At 24 h post the last injection of 
MBs, DBCO-Cy5 (5.0 mg/kg) was i.v. injected. BALB/c mice were placed on the sample stage 
equipped with anesthesia input and output ports, and imaged by the Bruker Xtreme In-Vivo 
Imaging System at 1, 6, 12, 24, and 48 h p.i. of DBCO-Cy5, respectively. Tumors, liver, lung, 
kidneys, heart, spleen, and brain were harvested at 48 h p.i. of DBCO-Cy5, and imaged ex vivo. 
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Ex vivo images were quantified by measuring FI at selected ROIs. All values were expressed as 
means ± standard deviation (n = 3).  
 
6.3 Results and Discussion 
Ac4ManAz-loaded liposomes functionalized with activated carboxylates were prepared via 
extrusion of the lipid mixture of hydrogenated L-α-phosphatidylcholine (HSPC), cholesterol and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[succinimidyl (polyethylene glycol)-2000] 
(DSPE-PEG2k-NHS). The prepared liposomes had a mean diameter of 180 nm and a sugar 
loading of 5.3% (w/w) (Fig. 6.1a). Amine-functionalized, perfluorobutane gas filled MBs with a 
mean diameter of 870 nm were prepared using the one-step sonication method. Ac4ManAz-
loaded liposomes were then conjugated to MBs via the coupling reaction between activated 
carboxylates and amine groups. The resulting Ac4-MB had a mean diameter of 1.03 μm and a 
narrow polydispersity index (PDI) of 0.22 (Fig. 6.1b). Blank MB without Ac4ManAz was 
prepared similarly. Ac4-MB showed excellent stability under physiological conditions, as 
evidenced by the negligible change in diameter and number density over 6 days (Fig. 6.1c). 
However, in the presence of high US pressures, the MBs collapsed. The US pressures applied to 
collapse 5% and 50% of the Ac4-MB population were 2.50 and 4.58 MPa, respectively (Fig. 
6.1d). 
 
I next studied whether Ac4-MB was able to metabolically label 4T1 breast cancer cells with 
azido groups when exposed to an US pressure field. 4T1 cells in Ac4-MB containing medium 
were treated with US for 1 min, further incubated for 3 days, and then treated with DBCO-Cy5 
for 1 h to detect the expression of azido groups. The group without US treatment was used as 
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control. As shown in Fig. 6.1e, minimal Cy5 fluorescence intensity (FI) was observed on the 
surface of 4T1 cells in the absence of US treatment, indicating the great stability of MBs during 
incubation. Because of its relatively large size, Ac4-MB was unable to enter the 4T1 cells and 
thus failed to release Ac4ManAz in cells for metabolic labeling. In comparison, 4T1 cells 
exposed to US showed strong Cy5 FI on the cell surface, suggesting that Ac4ManAz-loaded 
liposomes were successfully released from the MBs, entered 4T1 cells via endocytosis, and 
released Ac4ManAz for subsequent metabolic labeling of cells.  
 
After demonstrating in vitro that Ac4-MB was able to metabolically label 4T1 breast cancer 
cells with azido groups only in the presence of US, we then went on to study whether targeted 
US pulses in the tumor area could be used to induce selective sugar labeling of tumor cells. As a 
proof-of-concept study, we first investigated whether targeted US in the tumor area could break 
intratumorally injected Ac4-MB and induce metabolic labeling of tumor cells. Ac4-MB was 
injected directly into the subcutaneous 4T1 tumors on the flanks of BALB/c mice with 
simultaneous treatment of targeted US. The right tumors were treated with high-amplitude US 
pressure pulses (the US system’s output was set to the maximum of 100% to collapse MBs), 
while the left tumors were treated with low-amplitude US pressure pulses (the US system’s 
output was set to a very low amplitude of 4% so that the MBs would not collapse and yet still 
provide US imaging capability). Ac4-MB injected into the right tumors collapsed and rapidly 
diffused away during injection in the presence of 100% US (upper panel, Fig. 6.2a). In 
comparison, most of Ac4-MB injected into the left tumors with 4% US treatment remained intact 
and deposited near the injection site (lower panel, Fig. 6.2a). Western blot analyses of tumor 
tissues at 72 h post injection (p.i.) of Ac4-MB showed the existence of more azido-modified 
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protein bands in the right tumors treated with 100% US than in the left tumors treated with 4% 
US, suggesting the enhanced metabolic labeling of tumor cells in the presence of high US 
pressure. 
 
To understand how the enhanced azido expression in the right tumors would improve the 
tumor accumulation of DBCO-cargo via the Click reaction, in a separate study, DBCO-Cy5 was 
intravenously (i.v.) injected via the tail vein and its biodistribution was monitored via in vivo 
fluorescence imaging. At 24 h or 48 h p.i. of DBCO-Cy5, a distinct difference in Cy5 FI between 
the right tumors treated with 100% US and left tumors treated with 4% US was observed (Fig. 
6.2b), while mice injected with blank MB showed negligible difference in Cy5 FI between the 
right and left tumors (Fig. 6.2b). Ex vivo fluorescence imaging showed a 1.35-fold Cy5 FI in the 
right tumor compared to the left tumor in Ac4-MB group (Fig. 6.2c). In comparison, negligible 
difference in Cy5 FI between the right and left tumors was observed in the blank MB group (Fig. 
6.2c). It is noteworthy that the left tumors of Ac4-MB group with 4% US treatment showed a 
statistically non-significant increase of Cy5 FI compared to the tumors of the blank MB group 
(Fig. 6.2c), suggesting the good stability of Ac4-MB in the tumor environment. Confocal images 
of the right tumor sections also showed much stronger Cy5 FI than the left tumor sections in 
Ac4-MB group. These findings are significant wherein they demonstrate that targeted US 
pressure in the tumor area collapsed the intratumorally injected Ac4-MB and facilitated the 
release and metabolic expression of Ac4ManAz. The expressed azido groups were able to 
significantly enhance the tumor accumulation of DBCO-Cy5 via the efficient Click reaction. 
 
 - 103 - 
After demonstrating that targeted US was able to collapse intratumorally injected Ac4-MB, I 
next investigated whether targeted US in the tumor area could collapse Ac4-MB that were 
injected systemically and subsequently induce the tumor accumulation and metabolic expression 
of Ac4ManAz. BALB/c mice bearing subcutaneous 4T1 tumors were divided into four groups: 
Ac4-MB with US treatment on the left tumors (Group 1); blank MB with US treatment on the left 
tumors (Group 2); Ac4-MB without US treatment (Group 3); and PBS without US treatment 
(Group 4). MB injections and targeted US exposures were given once daily for three days (Day 1, 
2, and 3). DBCO-Cy5 was i.v. injected on Day 4 and its biodistribution was monitored via in 
vivo fluorescence imaging (Fig. 6.3a). As shown in Fig. 6.3b, a clear Cy5 fluorescence contrast 
between the left tumors with US treatment and the right tumors without US treatment was 
observed in Group 1 mice at 24 h and 48 h p.i. of DBCO-Cy5. In comparison, negligible 
difference in DBCO-Cy5 signal between the left and right tumors was observed in Group 2 mice 
without the sugar treatment and Group 3 mice without the US treatment. Ex vivo imaging 
showed a 1.65-fold Cy5 FI in the left tumors compared to the right tumors in Group 1 mice, with 
no significant difference in Cy5 FI between the left and right tumors observed in all other groups 
(Fig. 6.3c-d). In comparison, healthy organs including liver, spleen, lung, brain, heart, and 
kidney showed negligible difference for the amount of retained Cy5 among all groups. These 
findings demonstrated that targeted US could improve the accumulation and expression of 
Ac4ManAz specifically in the tumor area, presumably as a result of the easier tumor penetration 
of released Ac4ManAz-loaded liposomes in the presence of the US exposure.  
 
6.4 Conclusion 
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In summary, I developed Ac4-MB for cancer targeted labeling and imaging with the 
assistance of targeted US. Targeted US could induce the collapse of Ac4-MB (as being visualized 
under US imaging) and the release and metabolic expression of azido-sugars within the tumor, 
which significantly increased the tumor accumulation of DBCO-Cy5 by 65% via the Click 
reaction compared to the group without US treatment. More importantly, the accumulation of 
DBCO-Cy5 in healthy tissues showed negligible change. Different from endogenous protein 
receptors that failed to improve the tumor pharmacokinetics of antibody-drug conjugate
25
 and 
nanoparticle-targeting ligand conjugate
26-29
, the exogenously introduced azido groups in our 
strategy can potentially significantly enhance the tumor pharmacokinetics of DBCO-therapeutic 
agents. Ac4-MB coupled with the use of targeted US could be a simple but powerful tool for in 
vivo cancer targeting and targeted cancer therapies. 
 
6.5 Figures and Schemes 
 
Scheme 6.1. (a) Metabolic labeling of Ac4ManAz and subsequent targeting of DBCO-cargo via copper-
free Click chemistry. (b) Ultrasound-assisted accumulation and metabolic expression of Ac4ManAz in the 
tumor area and subsequent tumor targeted delivery of DBCO-cargo via Click chemistry. 
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Figure 6.1. (a) Diameter and diameter distribution of Ac4ManAz loaded liposome. (b) Diameter 
and diameter distribution of Ac4-MB. Inset: microscopic image of Ac4-MB. (c) Change of 
diameter and number density of Ac4-MB over time in 10% fetal bovine serum. (d) Percentage 
postexcitation curve for Ac4-MB, plotted against peak rarefactional pressure amplitude (PRPA). 
(e) CLSM images of 4T1 cells after treated with Ac4-MB with or without US treatment for three 
days, followed by labeling with DBCO-Cy5 for 1 h. Cells treated with blank MB and labeled 
with DBCO-Cy5 were used as control. The cell nucleus was stained with DAPI (blue). Scale bar: 
10 μm. 
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Figure 6.2. (a) US imaging of the tumor area of BALB/c mice during the intratumoral injection 
of Ac4-MB. 100% and 4% US was applied to the right and left tumors, respectively, upon MB 
injection (1 min), and continuously applied for another 1 min after MB injection. The yellow 
arrow indicates the syringe, and the red arrow indicates the MBs. (b) In vivo whole body 
fluorescence imaging of BALB/c mice pretreated with Ac4-MB and blank MB, respectively, at 
48 h p.i. of DBCO-Cy5. (c) Ex vivo FI of tumors from BALB/c mice pretreated with Ac4-MB 
and blank MB, respectively, at 48 h p.i. of DBCO-Cy5. Data were presented as mean ± SEM 
(n=3) and analyzed by one-way ANOVA (Fisher; 0.01 < *P ≤ 0.05; ***P ≤ 0.01; **P ≤ 
0.001). 
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Figure 6.3. (a) Time frame of in vivo imaging study. When 4T1 tumors in both flanks of 
BALB/c mice reached a diameter of approximately 5 mm, the hair over the tumor area was 
shaved and depilated, and Ac4-MB (50 mg/kg in sugar equivalent) or blank MB (same amount of 
MB) was i.v. injected with simultaneous US exposures on the left tumors once daily for three 
days. On Day 4, DBCO-Cy5 (5 mg/kg) was i.v. injected. (b) In vivo whole body fluorescence 
imaging of BALB/c mice at 12 h, 24 h, and 48 h p.i. of DBCO-Cy5, respectively. (c) Ex vivo 
imaging of tumors and major organs at 48 h p.i. of DBCO-Cy5. 1-liver, 2-spleen, 3-lung, 4-brain, 
5-heart, 6,7-kidneys, 8-right tumor, 9-left tumor. (d) Quantification of Cy5 FI in tumors from (c). 
Data were presented as mean ± SEM (n=3) and analyzed by one-way ANOVA (Fisher; 0.01 < 
*P ≤ 0.05; ***P ≤ 0.01; **P ≤ 0.001). 
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CHAPTER 7 
AZIDO-GALACTOSE COUPLED WITH CLICK CHEMISTRY FOR 
LIVER CANCER TARGETING 
 
7.1 Introduction 
Metabolic glycoengineering process of unnatural sugars provides a powerful tool to label 
cell surface with chemical functional groups for glycan imaging and cell targeting.
1-4
 The sugar-
mediated cell labeling, coupled with efficient Click chemistries, has shown great potential for 
cancer targeting over the past few years due to its advantages in high targeting efficiency, 
absence of immunogenicity, and easy manufacture.
5-9
 In the first step, unnatural sugars carrying 
biorthogonal chemical groups (e.g., azide) were delivered to and metabolized in cancers, 
followed by the targeting of DBCO-bearing therapeutic agents or nanomedicines via Click 
chemistry in the second step. However, one issue central to the use of the two-step strategy for 
cancer targeting lies in the cancer-selective sugar labeling. Numerous efforts have been made to 
deliver unnatural sugars in the form of nanoparticles by taking advantage of the EPR effect. For 
example, Kim et al. reported the use of chitosan nanoparticle for the delivery of Ac4ManAz.
10
 
Chen group reported the use of azido-sugar encapsulated liposomes for tumor labeling and 
subsequent targeting.
11, 12
 I also developed trigger-activatable Ac3ManAz derivatives for cancer-
selective labeling (Chapter 2-3). Other than these strategies, I envision that different types of 
unnatural sugars likely exhibit distinct metabolic labeling efficiency in varying cancer cell lines. 
Taking N-azidoacetylmannosamine (ManAz) and N-azidoacetylgalactosamine (GalAz) for 
example, they undergo different metabolic pathways and thus may exhibit different tumor 
accumulation profiles and cancer-labeling rates. 
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Hepatocellular carcinoma (HCC) has become a leading cause of cancer patient deaths 
worldwide over the past decades.
13-15
 Current clinical HCC treatment is mainly attributed to 
surgery and chemotherapy. Chemotherapy that uses therapeutic drugs to provide systemic 
treatment is a mainstream treatment of HCC, especially for advanced HCC.
16-18
 For example, 
Sorafenib, a receptor tyrosine kinase inhibitor, has been approved by FDA to treat advanced 
HCC. However, one key issue of chemotherapy is the severe side effect, resulting in the great 
demand of targeted chemotherapy aiming to deliver the drugs specifically to cancers.
19-21
 Despite 
the existence of various cancer-targeting ligands such as folate, aptamers, and monoclonal 
antibody (mAb), targeted therapy for HCC is rare because of the absence of characteristic cell-
surface receptors. Asialoglycoprotein receptor (ASGPR) is one of the very few hepatic cell-
featured receptors, and is able to selectively attach and clear glycoproteins with terminal 
galactose residue from the bloodstream.
22-24
 Despite the unknown targeting mechanism, 
galactose residues are thought to play an important role in binding to ASGPR. Despite the 
failures of utilizing galactose as an effective targeting ligand for drug and gene delivery, it can be 
envisioned that galactose might exhibit different biodistribution profile from other types of 
monosaccharide including mannose. In this study, I compared the HCC-labeling efficiency 
between ManAz and GalAz, and evaluated the feasibility of applying azido-sugar labeling and 
DBCO-drug conjugate to the targeted treatment of HCC. 
 
7.2 Materials and Methods 
7.2.1 Synthesis of ManAz and GalAz. D-Mannosamine hydrochloride or D-galactosamine 
hydrochloride (1.0 mmol) and triethylamine (1.0 mmol) were dissolved in methanol, followed by 
the addition of N-(2-azidoacetyl) succinimide (1.1 mmol). The mixture was stirred at room 
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temperature for 24 h. Solvent was removed under reduced pressure, and the crude product was 
purified by silica gel column chromatography using ethyl acetate to ethyl acetate/methanol (2/1, 
v/v) as the eluent to yield a white solid. ESI MS (m/z): calculated for C8H14N4O6Na [M+Na]
+
 
285.1, found 285.1. 
 
7.2.2 General procedures for confocal imaging of azido-sugar labeled cells. HepG2 cells were 
seeded onto coverslips in a 6-well plate at a density of 4×10
4
 cells per well and allowed to attach 
for 12 h. GalAz or ManAz (200 μM) was added and the cells were incubated at 37oC for 72 h. 
After washing with PBS, cells were incubated with DBCO-Cy5 (50 μM) for 1 h and fixed with 4% 
paraformaldehyde (PFA) solution, followed by staining of cell nuclei with DAPI. The coverslips 
were mounted onto microscope slides and imaged under a confocal laser scanning microscope. 
 
7.2.3 General procedures for flow cytometry analysis of azido-sugar labeled cells. HepG2 cells 
were seeded in a 24-well plate at a density of 1×10
4
 cells per well and allowed to attach for 12 h. 
GalAz or ManAz (200 μM) was added and incubated with cells for 72 h. After washing with 
PBS, cells were incubated with DBCO-Cy5 (50 μM) for 1 h. Cells were lifted by incubating with 
trypsin solution and analyzed by flow cytometry. 
 
7.2.4 Labeling kinetics of GalAz and ManAz. HepG2 cells were seeded in black 96-well plates 
and incubated with various concentrations of GalAz or ManAz (10 μM, 50 μM, 200 μM, 1 mM, 
and 5 mM) for different time (1 h, 6 h, 12 h, 24 h, 48 h, 72 h, 96 h, and 120 h). After washing 
with PBS, cells were incubated with DBCO-Cy5 (20 μM) for 1 h. Average Cy5 FI per cell was 
measured on IN Cell Analyzer 2200.  
 - 113 - 
7.2.5 Synthesis of 
14
C-Gal and 
14
C-Man. 1-
14
C acetic acid (1.0 molar equiv.) was dissolved in 
PBS (pH 7.4), followed by the addition of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC, 2 molar equiv.) and N-hydroxybenzotriazole (HOBt, 2 molar equiv.). The mixture was 
stirred at room temperature for 48 h. D-Mannosamine hydrochloride or D-galactosamine 
hydrochloride (1.0 molar equiv.) that had been neutralized by sodium bicarbonate was then 
added, and the mixture was further stirred at room temperature for 24 h. After filtration, the 
solution was concentrated for use without further purification. 
 
7.2.6 
14
C-Gal and 
14
C-Man mediated cell labeling. HepG2 cells were seeded onto coverslips in 
a 6-well plate at a density of 4×10
4
 cells per well and allowed to attach for 12 h. 
14
C-Gal or 
14
C-
Man (1 μCi) was added and incubated with cells for 12 h. After washing with PBS, the cells 
were further incubated in fresh medium at 37
o
C for 48 h. Cells were then harvested, lysed in the 
presence of EDTA-free protease inhibitor cocktail, and centrifuged to removal cell debris. The 
supernatant was collected for the extraction of proteins following the reported procedures: 9 
volumes of ethanol were added to 1 volume of aqueous protein solution, and the solution was 
cooled at -80
o
C for 4 h.  The protein pellet was collected via centrifugation and re-dissolved in 
sodium dodecyl sulfate buffer with the assistance of heating. 
14
C radioactivity of the extracted 
proteins was measured on a Tri-carb liquid scintillation counter. Ultima Gold
TM
 liquid 
scintillation cocktail was used for the radioactivity measurement.  
 
7.2.7 Biodistribuition of 
14
C-Gal and 
14
C-Man in athymic nude mice. HepG2 tumors were 
established in 8 week-old female athymic nude mice by subcutaneous injection of HepG2 cells 
(1.5×10
6
 cells) in Hank’s balanced salt solution (HBSS)/matrigel (1/1, v/v) into both flanks. 
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When the tumors reached ~70 mm
3
, 
14
C-Gal or 
14
C-Man (10 µCi) was intravenously (i.v.) 
injected via tail vein. After 24 h or 5 days, tumors and organs were harvested, weighed, 
homogenized in lysis buffer, and measured for the radioactivity on a Tri-Carb liquid scintillation 
counter. A gradient concentration of 
14
C-Gal or 
14
C-Man was used for determining the standard 
curve of 
14
C radioactivity. The data were presented as %I.D./g. 
 
7.2.8 In vivo tumor labeling of GalAz and ManAz. HepG2 tumors were established in 8 week-
old female athymic nude mice by subcutaneous injection of HepG2 cells (1.5×10
6
 cells) in 
Hank’s balanced salt solution (HBSS)/matrigel (1/1, v/v) into both flanks. When the tumors 
reached ~50 mm
3
, mice were i.v. injected with GalAz or ManAz (200 mg/kg) once daily for 
three days (Day 1-3). Mice i.v. injected with PBS were used as controls. On Day 4, DBCO-Cy5 
(5 mg/kg) was i.v. injected. Due to the intrinsic black color of HepG2 tumors, in vivo and ex vivo 
images of mice failed to show the Cy5 fluorescence signals in tumors. At 48 h p.i. of DBCO-Cy5, 
tumors were harvested from mice and bisected. Half of the tumor was directly frozen in O.C.T. 
compound, sectioned with a thickness of 8 μm, stained with DAPI (2 μg/mL), and imaged under 
a confocal laser scanning microscope. Organs and the other half of tumors were homogenized 
and lysed. The lysates were measured on a fluorescence spectrometer to determine the amount of 
Cy5 retained in the tissues based on the standard curve of Cy5 fluorescence intensity. Data were 
presented as % I.D./g. 
 
7.2.9 Acute efficacy study of GalAz/ManAz and DBCO-hz-Dox in athymic nude mice. HepG2 
tumor models were established in 6 week-old female 01B74 athymic nude mice by subcutaneous 
injection of HepG2 cells (1.5 million) into both flanks. When the tumors grew to a size of ~50 
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mm
3
, mice were randomly divided into six groups (group 1: Gal-N3/DBCO-hz-Dox; group 2: 
ManAz/DBCO-hz-Dox; group 3: DBCO-hz-Dox; group 4: GalAz; group 5: ManAz; n = 3). 
GalAz or ManAz (200 mg/kg) was i.v. injected once daily for three days (Day 1-3). On Day 4, 
DBCO-hz-Dox (10 mg/kg Dox equivalent) was i.v. injected. At 48 h p.i. of DBCO-hz-Dox, 
tumors were harvested from mice and bisected. Half of tumors were frozen with O.C.T. 
compound and sectioned on cryostat with a thickness of 6 μm. Cell apoptosis in tumors was 
analyzed via TUNEL assay using in situ cell death detection kit. TUNEL staining was performed 
following the manufacture’s manual. The tumor sections were imaged with the confocal laser 
scanning microscopy at 20× magnification. Organs and the other half of the tumors were 
homogenized and lysed in lysis buffer, and quantified for the retained doxorubicin via HPLC. 
 
7.3 Results and Discussion 
I first studied the labeling capability of GalAz and ManAz in HepG2 liver cancer cells in 
vitro. HepG2 cells were incubated with GalAz or ManAz for three days and the potentially 
expressed azido groups on the cell surface were detected by DBCO-Cy5 via Click chemistry (Fig. 
7.1a). As shown in Fig. 1b, cells treated with GalAz or ManAz showed much stronger Cy5 
fluorescence intensity on the cell surface compared to control cells treated with PBS, indicating 
their successful expression of azido group. It could be noted that passive uptake of DBCO-Cy5 
by HepG2 cells was negligible compared to covalently attached DBCO-Cy5 by cell-surface 
azido group via Click chemistry. Flow cytometry analysis of HepG2 cells treated with GalAz or 
ManAz also showed significantly enhanced DBCO-Cy5 attachment than cells treated with PBS 
(Fig. 7.1c). HepG2 cells treated with the same concentration of GalAz or ManAz (200 µM) 
followed by DBCO-Cy5 treatment showed similar Cy5 fluorescence intensity, suggesting a 
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similar level of azido expression (Fig. 7.1b-c). It is noteworthy that the labeling efficiency of 
GalAz and ManAz was significantly lower than their acetylated analogs, Ac4GalAz and 
Ac4ManAz, respectively, presumably due to the lower cellular uptake of more hydrophilic GalAz 
and ManAz. Nevertheless, the great water solubility of GalAz and ManAz would enable their 
facile use for tumor labeling in vivo. The exposure of hydroxyl groups may also be indispensable 
for specific binding to cell-surface ASGPRs of HCC. 
 
I next studied the in vitro labeling kinetics of GalAz and ManAz in HepG2 cells, in an effort 
to compare their metabolic labeling rates. HepG2 cells were incubated with different 
concentrations of GalAz or ManAz (10 μM, 50 μM, 200 μM, 1 mM, and 5 mM) for different 
time (1, 3, 6, 12, 24, 48, 72, 96, and 120 h), and the expressed azido group on the cell surface 
were detected by incubating with DBCO-Cy5. As a result, both GalAz- and ManAz-mediated 
labeling of HepG2 cancer cells was time- and concentration-dependent (Fig. 7.1d), with the 
azido expression approaching to a plateau value after 72 h. GalAz showed a slightly faster 
metabolic labeling rate than ManAz at lower concentrations (Fig. 7.1e), but this difference 
became smaller at higher sugar concentrations. When the incubation time was long enough for 
sufficient sugar labeling, the Cy5 fluorescence intensity of cells treated with GalAz was slightly 
weaker than cells treated with ManAz, which might be explained by the different positioning of 
azido groups expressed by GalAz and ManAz. Different from GalAz, ManAz is converted to 
azido sialic acid prior to being incorporated into glycoproteins and is thus positioned at the end 
of glycoprotein chains. Azido group expressed by GalAz, however, is positioned in the middle of 
glycan chains and its reaction with DBCO-Cy5 in the medium might suffer from steric 
hinderance. Together, these experiments showed that GalAz exhibited a slightly faster metabolic 
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labeling rate than ManAz at low sugar concentrations but showed a similar labeling kinetics to 
ManAz at high sugar concentrations in terms of both labeling rate and up-limit level of azido 
expression. 
 
I next aimed to compare the in vivo biodistribution profiles of GalAz and ManAz in athymic 
nude mice bearing subcutaneous HepG2 tumors. However, it was unlikely to directly quantify 
GalAz and ManAz in tissues because of the lack of measurable properties and the changes in 
chemical structure during sugar metabolism. In addition, chemical modification of GalAz or 
ManAz with fluorescent or radioactive tags will significantly change the molecular weight and 
might impair their physiochemical and pharmacokinetic properties. Therefore, I used 
14
C-Gal 
and 
14
C-Man with very similar structures to GalAz and ManAz as the representatives (Fig. 7.2a). 
It can be assumed that 
14
C-Gal/GalAz and 
14
C-Man/ManAz would exhibit similar properties 
including water solubility, blood-circulation half-life, and tissue penetration and cellular uptake. 
I also examined whether 
14
C-Gal and 
14
C-Man could also metabolically label HepG2 cells in 
vitro. HepG2 cells were co-incubated with 
14
C-Gal or 
14
C-Man for 12 h and further incubated in 
fresh medium for 48 h. After washing, cells were lysed and then proteins were precipitated from 
cell lysates and recovered for 
14
C-radioactivity measurement. As a result, proteins extracted from 
cells treated with 
14
C-Gal or 
14
C-Man showed a strong 
14
C-radioactivity (Fig. 7.2b). In 
comparison, negligible 
14
C-radioactivity was observed in the recovered proteins of HepG2 cells 
treated with 
14
C-acetic acid. These experiments suggested that 
14
C-Gal and 
14
C-Man can be 
metabolized by HepG2 cancer cells and incorporated into cellular proteins, presumably including 
cell-surface glycoproteins.  
 - 118 - 
 After demonstrating the feasibility of using 
14
C-Gal and 
14
C-Man as representatives of 
GalAz and ManAz, I then compared the biodistribution of 
14
C-Gal and 
14
C-Man in athymic nude 
mice bearing subcutaneous HepG2 tumors. HepG2 tumors were established in athymic nude 
mice via subcutaneous injection of HepG2 cells into the flanks. When the tumors grew to ~60 
mm
3
, mice were divided into 4 groups: 
14
C-Gal + 6 h; 
14
C-Man + 6 h; 
14
C-Gal + 5 days; 
14
C-Man 
+ 5 days. Mice were i.v. injected with 
14
C-Gal or 
14
C-Man. At 6 h or 5 days post injection (p.i.) 
of 
14
C-Gal or 
14
C-Man, tumors and organs were harvested, lysed, and measured for 
14
C 
radioactivity. At 6 h p.i., all tissues including tumor, heart, kidney, liver, lung, and spleen 
showed negligibly different accumulation between 
14
C-Gal and 
14
C-Man (Fig. 7.2c), suggesting 
very similar pharmacokinetics property of 
14
C-Gal and 
14
C-Man. At 5 days p.i., 
14
C-Gal showed 
much higher tumor retention than 
14
C-Man, with a 195% enhancement (Fig. 7.2c). Compared 
to
14
C-Man, 
14
C-Gal also showed a higher retention in liver, kidney, and spleen. These 
differences in the tissue accumulation of 
14
C-Gal and 
14
C-Man might be explained by the faster 
combined kinetics of cellular uptake and sugar metabolism. I demonstrated in vitro that GalAz 
showed a slightly faster metabolic labeling rate than ManAz at low sugar concentrations (Fig. 
7.1d). In the case of in vivo labeling, the extracellular concentration of 
14
C-Gal or 
14
C-Man was 
very low, which might be reflected on the labeling rate differences between 
14
C-Gal and 
14
C-
Man. Another possible reason for the higher tissue retention of 
14
C-Gal than 
14
C-Man is the 
preferential cellular uptake of 
14
C-Gal, especially in HepG2 tumor cells and hepatic cells which 
are reported to be rich in ASGPRs. Compared to liver, tumor showed a greater difference in the 
long-term retention of 
14
C-Gal and 
14
C-Man, presumably because of the higher sugar metabolism 
rate in cancer cells than in normal cells. Different from liver, kidney, spleen, and tumor which 
showed higher retention of 
14
C-Gal than 
14
C-Man, lung and heart tended to retain more 
14
C-Man. 
 - 119 - 
These experiments demonstrated the better long-term tumor retention and metabolic labeling of 
14
C-Gal than 
14
C-Man and probably suggested the same scenarios for the case of GalAz and 
ManAz. 
 
I next studied whether i.v. injected GalAz and ManAz could efficiently label HepG2 tumors 
with azido group in vivo and subsequently mediate targeted delivery of DBCO-Cy5. HepG2 
tumors were established in athymic nude mice by subcutaneous injection of HepG2 cancer cells 
into the flanks. When the tumors reached ~50 mm
3
, GalAz or ManAz was i.v. injected once daily 
for three days (Day 1-3). DBCO-Cy5 was i.v. injected on Day 4 (Fig. 7.3a). Because of the 
intrinsic black color of HepG2 tumors, in vivo whole-body imaging and ex vivo imaging of 
harvested tissues failed to provide useful information about Cy5 accumulation in tissues. I 
homogenized the tissues at 48 h p.i. of DBCO-Cy5, and quantified the retained Cy5. As shown in 
Fig. 7.3b, mice treated with GalAz or ManAz showed significantly improved tumor 
accumulation of DBCO-Cy5 than mice treated with PBS, presumably as a result of the metabolic 
labeling of tumor cells with azido group and the subsequent targeting of DBCO-Cy5 via Click 
chemistry. Accumulation of DBCO-Cy5 in liver and lung was also enhanced in GalAz or 
ManAz-treated mice compared to PBS-treated mice. In comparison with ManAz group, GalAz 
group mice showed statistically significantly improved tumor accumulation of DBCO-Cy5, 
presumably due to the more azido expression by GalAz than ManAz, which matched with the 
better long-term tumor retention of Gal-
14
C than Man-
14
C in Fig.2c. Confocal images of tumor 
tissues from mice treated with GalAz also showed stronger Cy5 fluorescence intensity compared 
to ManAz group (Fig. 7.3c). These experiments demonstrated that GalAz outperformed ManAz 
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in the labeling of HepG2 tumors in vivo and could mediate a better targeting effect of DBCO-
cargo. 
 
After demonstrating that GalAz- and ManAz-mediated labeling of HepG2 tumors could 
enhance the tumor accumulation of DBCO-Cy5 via Click chemistry, I next investigated whether 
GalAz or ManAz treatment would improve the tumor accumulation of DBCO-drug conjugate. 
DBCO-doxorubicin conjugate with a pH-responsive hydrazone linker, DBCO-hz-Dox, was 
synthesized following the reported procedures (Fig. 7.4a). DBCO-hz-Dox showed great stability 
under physiological conditions (pH 7.4), but underwent rapid degradation and Dox release at pH 
5.0. In an acute antitumor efficacy study, HepG2 tumors were implanted in athymic nude mice 
by subcutaneous injection of HepG2 cancer cells. When the tumors reached ~70 mm
3
, mice were 
divided into 6 groups (Group 1: GalAz+DBCO-hz-Dox; Group 2: ManAz+DBCO-hz-Dox; 
Group 3: DBCO-hz-Dox; Group 4: GalAz; Group 5: ManAz; and Group 6: PBS). Mice were i.v. 
injected with GalAz or ManAz once daily for three days (Day 1-3). DBCO-hz-Dox was i.v. 
injected on Day 4. At 48 h p.i. of DBCO-hz-Dox, tumor tissues were harvested for the analyses 
of drug retention and tumor cell apoptosis (Fig. 7.4b). As a result, mice treated with GalAz or 
ManAz showed significantly enhanced tumor accumulation of DBCO-hz-Dox than mice treated 
with PBS. All drug treatment groups showed much higher tumor apoptosis index than GalAz, 
ManAz, and PBS groups (Fig. 7.4c-d). Compared to DBCO-hz-Dox only, GalAz+DBCO-hz-
Dox (17.9%) and ManAz+DBCO-hz-Dox (11.2%) imparted a greater tumor apoptosis than 
group mice compared to DBCO-hz-Dox only (8.7%) (Fig. 7.4c-d). Compared to ManAz, GalAz 
further improved the tumor accumulation of DBCO-hz-Dox and resulted in a greater tumor 
apoptosis index (Fig. 4c-d). These experiments demonstrated that tumor labeling by GalAz or 
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ManAz could improve the tumor accumulation of DBCO-drug conjugate and impart a higher 
acute antitumor efficacy, and that GalAz outperformed ManAz in HepG2 tumor labeling and 
subsequent targeting of DBCO-drug conjugate. 
 
7.4 Conclusion 
In conclusion, I compared the labeling efficiency of GalAz and ManAz in HapG2 HCC both 
in vitro and in vivo, and evaluated the feasibility of GalAz coupled with DBCO-drug conjugate 
for the targeted treatment of HCC. Compared to ManAz, GalAz showed a slightly faster cell-
labeling rate at low sugar concentrations, resulting in a significantly higher long-term retention in 
HepG2 tumor tissues. GalAz-mediated labeling of HepG2 tumors could significantly improve 
the tumor accumulation of DBCO-Cy5 via Click chemistry. Subsequent acute antitumor efficacy 
study also showed the enhanced tumor accumulation of DBCO-drug conjugates and the resulting 
improved anticancer efficacy in GalAz-treated mice compared to PBS-treated mice. ManAz 
could also metabolically label HepG2 tumors with azido groups and result in the significantly 
improved tumor accumulation of DBCO-Cy5 and DBCO-drug conjugates, however, the labeling 
efficiency and subsequent Click chemistry-mediated targeting effect was significantly lower than 
GalAz. This study, for the first time, demonstrates that different types of unnatural sugars have 
distinct labeling efficiency in varying cancers. There may exist unnatural sugars that intrinsically 
have excellent cancer-selective labeling capability. The combinatory therapy of GalAz and 
DBCO-drug conjugates will also provide a new avenue for targeted treatment of HCC. 
 
7.5 Figures and Schemes 
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Figure 7.1. (a) Schematic illustration of GalAz- or ManAz-mediated metabolic labeling of cancer 
cells with azido group and subsequent detection of the expressed azido group using DBCO-Cy5 via 
Click chemistry. (b) CLSM images of HepG2 cells after treated with GalAz (200 µM), ManAz (200 
µM), and PBS, respectively for 72 h and labeled with DBCO-Cy5 (20 µM, red) for 1 h. Cell nuclei 
were stained with DAPI (blue). Scale bar: 10 µm. (c) Flow cytometry profiles of HepG2 cells 
following the same treatment in (b). (d) In vitro labeling kinetics of GalAz in HepG2 cells. HepG2 
cells were incubated with different concentrations of GalAz (10 µM, 50 µM, 200 µM, 1 mM, and 5 
mM) for different time (1, 6, 12, 24, 48, 72, 96, and 120 h), and labeled with DBCO-Cy5 (20 µM) for 
1 h. Average Cy5 fluorescence intensity was measured on a GE-analyzer. (e) Comparison of in vitro 
labeling kinetics of GalAz and ManAz at a concentration of 50 µM and 1 mM, respectively. 
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Figure 7.2. (a) Structure of 
14
C-Gal and 
14
C-Man, as representatives of GalAz and ManAz, 
respectively. (b) 
14
C radioactivity of proteins extracted from HepG2 cells after treatment with 
14
C-Gal, 
14
C-Man, and PBS, respectively. (c) Biodistribution of 
14
C-Gal and 
14
C-Man in athymic 
nude mice bearing subcutaneous HepG2 tumors at 6 h and 5 days p.i., respectively. Tissues were 
harvested from mice, homogenized, lysed, and measured for the radioactivity on a Tricarb liquid 
scintillation counter. All numerical data were presented as mean±SEM (n=3) and analyzed by 
Student’s t-test (two-tailed, 0.01 < *P ≤ 0.05, 0.001 < **P ≤ 0.01, and ***P ≤ 0.001). 
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Figure 7.3. (a) Time frame of in vivo imaging study. Athymic nude mice bearing subcutaneous 
HepG2 tumors were i.v. injected with GalAz (200 mg/kg), ManAz (200 mg/kg), and PBS, 
respectively once daily for three days (Day 1-4). DBCO-Cy5 (5 mg/kg) was i.v. injected on Day 
4. Tissues were harvested at 48 h p.i. of DBCO-Cy5 for quantifying retained Cy5 using 
fluorescence method. (b) Biodistribution of Cy5 in tissues at 48 h p.i. of DBCO-Cy5. Data were 
presented as mean±SEM (n=3) and analyzed by Student’s t-test (two-tailed, 0.01 < *P ≤ 0.05, 
0.001 < **P ≤ 0.01, and ***P ≤ 0.001). (c) Representative CLSM images of tumor tissue 
sections from different groups. Cell nuclei were stained with DAPI (blue). Scale bar: 10 μm. 
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Figure 7.4. (a) Structure of pH-responsive DBCO-doxorubicin conjugate, DBCO-hz-Dox. (b) 
Time frame of acute efficacy study. Athymic nude mice bearing HepG2 tumors were i.v. injected 
with Gal-N3 (200 mg/kg) or Man-N3 (200 mg/kg) or PBS once daily for three days (Day 1-3). 
DBCO-hz-Dox (8.0 mg/kg, Dox equivalent) was i.v. injected on Day 4. Tissues were harvested 
from mice at 48 h p.i. of DBCO-hz-Dox. (c) Representative TUNEL staining sections of HepG2 
tumors from mice treated with GalAz+DBCO-hz-Dox, ManAz+DBCO-hz-Dox, DBCO-hz-Dox, 
GalAz, ManAz, and PBS, respectively. Scale bar: 50 μm. (d) Quantification of TUNEL stains via 
ImageJ. The apoptosis index was determined as the ratio of apoptotic cell number (TUNEL, red) 
to the total cell number (DAPI, blue). 20 tissue sections were counted per tumor; n=6. Statistical 
significance analysis was performed by Student’s t-test (two tailed, 0.01 < *P ≤ 0.05, 0.001 < 
**P ≤ 0.01, and ***P ≤ 0.001).  
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CHAPTER 8 
RECYCLABLE CELL-SURFACE CHEMICAL RECEPTORS FOR 
CANCER TARGETING 
 
8.1 Introduction 
Metabolic glycoengineering of unnatural sugars enables the expression of chemical groups 
on the cellular surface.
1-3
 These chemical tags (e.g., azides) can mediate targeted delivery of 
extracellular materials via efficient Click chemistry, especially copper-free click chemistry 
between azides and DBCO. Compared to conventional protein receptor-based cell targeting 
which utilizes the electrostatic interactions between proteins, Click chemistry possesses the 
advantages of high reaction efficiency, great compatibility and bioorthogonality, and easy 
manufacture.
4-7
 For these reasons, metabolic sugar labeling coupled with Click chemistry has 
been widely used for cancer targeting.
4, 8-10
 It has been demonstrated that cell-surface chemical 
tags can facilitate the cellular attachment of extracellular therapeutic agents bearing 
corresponding clickable functional groups.
11, 12
 However, the cellular uptake mechanism of these 
covalently attached agents was rarely understood. For example, Kim group reported the use of 
cell-surface azido groups to attach DBCO-modified nanoparticles,
13
 but the uptake mechanism of 
these attached nanoparticles remained elusive. In addition, because of its typical endocytosis 
mechanism, nanoparticle is not an appropriate candidate for studying the cellular uptake 
mechanism of covalently attached therapeutic agents.  
 
One key drawback of existing azide-alkyne Click chemistry based targeting strategies is the 
one-time-use limitation of the artificially introduced azido groups. The non-recyclability of cell-
surface chemical tags will necessitate the re-administration of unnatural sugars for continuous 
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targeted delivery of cargos, which may pose a great challenge in the development of Click 
chemistry-based targeting strategies. In contrast, endogenous protein receptors are able to release 
non-covalently bound targeting ligands in endosomes/lysosomes and then recycle back to cell 
surface for continuous targeting.
14-16
 Given that unnatural sugars are expressed in the form of 
glycoproteins, I hypothesize that these glycoproteins will be stimulated upon covalent attachment 
of targeting ligands and drag them into cells by forming vesicles. I further reason that these 
chemical tags might be able to recycle back to cell surface if the formed covalent bond between 
chemical tags and attached cargos can be cleaved in endosomes/lysosomes, similar to 
endogenous protein receptors. Among the developed reversible chemistries that are responsive to 
cellular triggers such as low pH, reductives, and enzymes, the reaction between hydrazide and 
ketone can rapidly happen under physiological pH (7.0-7.4), and the formed hydrazone bond can 
be cleaved in acidic endosomes/lysosomes (pH = 5.0-6.0).
17-19
 Here I use the pH-responsive 
hydrazide/ketone chemistry to investigate the cellular uptake process of cargo-hydrazide in 
ketone-modified cancer cells and study whether the ketone groups can recycle back to cell 
surface after releasing cargo-hydrazide in acidic endosomes/lysosomes that can cleave the 
formed hydrazone bond (Scheme 8.1).  
 
8.2 Materials and Methods 
8.2.1 Synthesis of tetraacetyl-N-(levulinic acyl)mannosamine (Ac4ManLev). D-Mannosamine 
hydrochloride (2.5 mmol) and triethylamine (2.5 mmol) were dissolved in methanol, followed by 
the addition of N-hydroxysuccinimidyl levulinate (2.75 mmol). The mixture was stirred at room 
temperature for 24 h. Solvent was removed under reduced pressure and the residue was re-
dissolved in pyridine. Acetic anhydride was added and the reaction mixture was stirred at room 
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temperature for another 24 h. After removal of the solvent, the crude product was purified by 
silica gel column chromatography to yield a white solid. 
 
8.2.2 General procedures for confocal imaging of azido-sugar labeled cells. LS174T cells were 
seeded onto coverslips in a 6-well plate at a density of 40k cells per well and allowed to attach 
for 12 h. Ac4ManLev (50 μM) was added and the cells were incubated at 37
o
C for 72 h. After 
washing with PBS, cells were incubated with Alex488-hydrazide (50 μM) for 1 h and fixed with 
4% PFA solution, followed by staining of cell nuclei with DAPI. The coverslips were mounted 
onto microscope slides and imaged under a confocal laser scanning microscope. 
 
8.2.3 General procedures for flow cytometry analysis of azido-sugar labeled cells. LS174T 
cells were seeded in a 24-well plate at a density of 10k cells per well and allowed to attach for 12 
h. Ac4ManLev (50 μM) was added and incubated with cells for 72 h. After washing with PBS, 
cells were incubated with Alex488-hydrazide (50 μM) for 1 h. Cells were lifted by incubating 
with trypsin solution and analyzed by flow cytometry. 
 
8.2.4 Uptake mechanism of Alex488-hydrazide in Ac4ManLev treated cells. LS174T cells were 
seeded onto cell culture dishes with cover glass bottom and incubated with Ac4ManLev (50 μM) 
for three days. After washing with PBS, the cells were incubated with Alex488-hydrazide (50 
μM) and lysotracker green (2 μg/mL) for 1 h. Hoechst 33342 (10 μg/mL) and CellMask orange 
plasma membrane stain (1 μg/mL) were then added to stain cell nuclei and membrane, 
respectively, for 10 min. After washing with PBS, the cells were further incubated in fresh 
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medium at 37
o
C for different time (0, 3, 6, 12, and 24 h) before being imaged under a 
fluorescence microscope to monitor the cellular internalization of Alex488-hydrazide. 
 
8.2.5 Uptake of Alex647-hydrazide in Ac4ManLev-treated cells post Alex488-hydrazide 
treatment. LS174T cells were seeded onto cell culture dishes with cover glass bottom and 
incubated with Ac4ManLev (50 μM) for three days. After washing with PBS, the cells were 
incubated with Alex488-hydrazide (50 μM) for 2 h. After washing with PBS, the cells were 
further incubated in fresh medium at 37
o
C for different time (0, 6, 12, and 24 h), at which time 
the medium was replaced with medium containing Alex647-hydrazide (50 μM) and the cells 
were further incubated for 1 h. Cells were then washed, fixed, stained with Hoechst 33342, and 
imaged under a confocal laser scanning microscope. 
 
8.3 Results and Discussion 
First, I synthesized Ac4ManLev and tested its pH-responsive reaction with hydrazide-
bearing dyes, Alex488-hydrazide and Alex647-hydrazide. At pH 7.4, Ac4ManLev and Alex488-
hydrazide rapidly reacted, as evidenced by the disappearance of Alex488-hydrazide peak and the 
formation of a new fluorescent compound. The new conjugate underwent rapid degradation 
when transferred to pH 5.0. I then investigated the metabolic labeling capability of Ac4ManLev 
in vitro. After incubating with Ac4ManLev for three days, LS174T colon cancer cells were 
labeled with Alex488-hydrazide to detect the potentially expressed ketone groups. CLSM images 
of LS174T cells treated with Ac4ManLev showed bright fluorescence signals on the cell surface, 
in sharp comparison to the negligible Alex488 fluorescence intensity observed in non-treated 
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cells (Fig. 8.1a). Flow cytometry analysis also showed the much stronger A488 FI in 
Ac4ManLev-treated LS174T cells than non-treated cells (Fig. 8.1b). 
 
I then studied the cellular uptake process of covalently attached A488-hydrazide in ketone-
modified LS174T cells. After being treated with Ac4ManLev for three days and labeled with 
Alex488-hydrazide for 1 h, LS174T cells were further incubated in fresh medium and the sub-
cellular location of Alex488 was monitored under a fluorescence microscope. The much brighter 
Alex488 fluorescence signals on the surface of Ac4ManLev-treated LS174T cells than control 
cells verified that the majority of Alex488 was covalently attached to cell surface via 
hydrazide/ketone chemistry. At the start of incubation (0 h), Alex488 signals well co-localized 
with membrane stain (Fig. 8.1c). At 3 h, a noticeable amount of Alex488 co-localized with 
lysotracker green, indicating that Alex488 reached endosomes/lysosomes (Fig. 8.1c). Allowing 
longer time (6 or 12 h) for cellular internalization, more Alex488 entered endosomes/lysosomes 
(Fig. 8.1c). It is noteworthy that Alex488 FI experienced a noticeable decrease at 12 h, probably 
because of the endosomal escape and subsequent cellular efflux of Alex488-hydrazide. These 
experiments demonstrated that covalently attached Alex-hydrazide by cell-surface ketone groups 
could go through the endocytosis pathway and reach endosomes/lysosomes for potential 
cleavage of the formed hydrazone bond. 
 
To evaluate whether the hydrazone bond between A488-hydrazide and ketone-modified 
glycoproteins would be cleaved in the acidic endosomes/lysosomes and whether the recovered 
ketone groups could recycle back to cell surface for continuous chemical targeting, I used 
Alex647-hydrazide as a follow-up reporter of cell-surface ketone population. Similar to 
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Alex488-hydrazide, Alex647-hydrazide showed good reactivity to ketone groups at pH 7.0 and 
the formed hydrazone bond rapidly degraded at pH 5.0. I incubated LS174T cells with 
Ac4ManLev for three days and then labeled cells with highly concentrated Alex488-hydrazide 
for 2 h to maximize the consumption of cell-surface ketone groups. After washing, cells were 
further incubated in fresh medium. At different time points (0, 6, 12, 24 h), Alex647-hydrazide 
was added and incubated with cells for 1 h to detect the recycled ketone groups on the cell 
surface. At 0 h, CLSM images showed uniform Alex488 signal on the cell membrane, and 
negligible Alex647 signal was observed on the cell surface, suggesting the largely complete 
consumption of reachable cell-surface ketone groups by Alex488-hydrazide (Fig. 8.2b). At 6 h, 
part of Alex488 signal entered the cells, and a small amount of Alex647 signals appeared on the 
cell membrane. At 12 h or 24 h, a strong Alex647 signal was observed in LS174T cells (Fig. 
8.2b), indicating that the ketone groups had recycled back to cell surface after dragging Alex488-
hydrazide into cells and enabled the successful conjugation of Alex647-hydrazide. Flow 
cytometry analyses of LS174T cells pre-labeled with Ac4ManLev and treated with Alex488-
hydrazide also showed continuous increase of Alex647 internalization over time (Fig. 8.2c). 
These results demonstrated that cell-surface ketone groups can be recycled back to membranes 
after dragging Alex488-hydrazide via endocytosis and continuously facilitate the targeted 
internalization of Alex647-hydrazide. 
 
8.4 Conclusion 
In conclusion, by metabolically labeling LS174T cancer cells with ketone groups and 
monitoring the targeted internalization of Alex488-hydrazide through biorthogonal chemistry 
between ketones and hydrazides, I demonstrated that covalently attached Alex488-hydrazide 
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would enter late endosomes/lysosomes. Subsequent use of Alex647-hydrazide as a follow-up 
fluorescence reporter further demonstrated the recyclability of cell-surface ketone groups, 
suggesting that the hydrazone bond between Alex 647-hydrazide and ketone-modified 
glycoproteins was cleaved in acidic lysosomes and recycled back to cell surface. Further work is 
still needed to quantify the recycling rate of cell-surface chemical receptors. In principle, the 
recyclability of chemical tags can be extended to other reversible chemistries. I believe the 
recyclability of cell-surface chemical receptors will facilitate the application of metabolic sugar 
labeling into cancer targeting.  
 
8.5 Figures and Schemes 
 
Scheme 8.1. Ac4ManLev mediated metabolic labeling of cells with ketone groups and targeted 
delivery of cargo-hydrazide. 
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Figure 8.1. (a) CLSM images of LS174T cells after pretreated with Ac4ManLev (50 μM) or PBS 
for 72 h and labeled with Alex488-hydrazide (50 μM, green) for 1 h. Cell nuclei were stained 
with DAPI (blue). Scale bar: 10 μm. (b) Flow cytometry analyses of LS174T cells following the 
same treatment as described in (a). (c) CLSM images of Ac4ManLev-labeled LS174T cells after 
incubation with Alex488-hydrazide for 0, 3, and 6 h, respectively. Cell nuclei, lysosomes, and 
membrane, were stained with Hoechst 33342 (blue), lysotracker red (orange), and deep-red 
CellMask (red), respectively. Scale bar: 10 μm. 
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Figure. 8.2. (a) Schematic illustration of recycling cell-surface ketone tags for continuous 
targeted internalization of hydrazine-cargos. (b) CLSM images of LS174T cells pretreated with 
Ac4ManLev (50 μM) for three days and incubated with A647-hydrazine (50 μM) for 1 h. After 
removal of A488-hydrazine solution, cells were further incubated for 0, 6, 12, and 24 h, 
respectively, followed by incubation with A647-hydrazide for 1 h. (c) Flow cytometry analyses 
of LS174T cells following the same treatment as described in (b). 
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